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Cameron D. Buchman 
 
DISCOVERY AND CHARACTERIZATION OF SMALL MOLECULE INHIBITORS 
OF THE ALDEHYDE DEHYDROGENASE 1/2 FAMILY 
 
The human aldehyde dehydrogenase (ALDH) superfamily consists of 19 isoenzymes that 
are critical for normal physiology as well as the removal of toxic aldehydes. Members of 
the ALDH1/2 family have vital roles in cell signaling during early development, ethanol 
metabolism, and the removal of aldehydes derived from oxidative stress. We sought to 
develop selective compounds toward ALDH2 to help determine its individual 
contribution to biological function, as many of the ALDH1/2 family possess overlapping 
substrate preferences. A high-throughput screen of over 100,000 compounds uncovered a 
class of aromatic lactones which inhibit the ALDH1/2 enzyme family. The lactones were 
then characterized using a combination of enzyme kinetics, X-ray crystallography, and 
cell culture experiments. We found that many of the lactones are over ten times more 
potent toward ALDH2 than daidzin, a previously described ALDH2 inhibitor. Our ability 
to produce many more ALDH isoenzymes allowed us to determine that daidzin is not as 
selective as previously believed, inhibiting ALDH2, ALDH1B1, and ALDH1A2 with 
equal potency. This inhibition pattern was seen with several of the aromatic lactones as 
well. Structural studies show that many of the lactones bind between key aromatic 
residues in the ALDH1/2 enzyme substrate-binding sites. One lactone in particular 
mimics the position of an aldehyde substrate and alters the position of the catalytic 
vii 
cysteine to interfere with the productive binding of NAD
+
 for enzyme catalysis. Further 
characterization of related compounds led to the realization that the mechanism of 
inhibition, potency, and selectivity differs amongst the lactones based off the substituents 
on the aromatic scaffold and its precise binding location. Two of these compounds were 
found to be selective for one of the ALDH1/2 family members, BUC22, selective for 
ALDH1A1, and BUC27, selective for ALDH2. BUC22 demonstrates ten-fold selectivity 
for ALDH1A1 over ALDH1A2 and does not inhibit the remaining ALDH1/2 enzymes. 
Additionally, treatment with BUC22 led to decreased growth of triple-negative breast 
cancer cells in culture. BUC27 inhibits ALDH2 with the same potency as daidzin. Both 
BUC22 and BUC27 could be further developed to use as chemical tools to better 
understand the functional roles of ALDH1A1 and ALDH2 in biological systems. 
 
Thomas D. Hurley, Ph.D., Chairman 
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1 
I. Introduction 
A. Aldehydes 
Aldehydes are organic compounds which contain a terminal carbonyl carbon (RCHO) 
where the R group can range from a hydrogen atom to complex organic structures. 
Aldehydes are found in a variety of endogenous and exogenous sources (Table 1). 
Amino acid catabolism produces aldehyde intermediates such as glutamic γ-
semialdehyde. The catabolism of various neurotransmitters including gamma-
aminobutyric acid (GABA), dopamine, adrenaline, and serotonin also produces several 
aldehyde intermediates.
1
 Many open chain forms of carbohydrates contain an aldehyde 
group, or contain a ketone which can tautomerize in solution to form an aldehyde group. 
The metabolism of ethanol and other foods can generate acetaldehyde as well as other 
aldehyde products. Aldehydes such as citral and benzaldeyde are also added to foods to 
provide flavor and odor.
2
 Several aldehydes play important roles in normal physiological 
processes. Retinaldehydes are an example that has multiple functions; as transcription 
factors critical for cellular growth and differentiation pathways, or as the ligand for 
rhodopsin, which covalently binds 11-cis-retinal and enables vision in low-light 
conditions.
3, 4
 
 
Despite being critical for many biological functions, many aldehydes are carcinogenic 
and cytotoxic. Oxidative degradation of membrane lipids, or lipid peroxidation, can 
produce over 200 aldehyde species, including 4-hydroxynonenal (4-HNE) and 
malondialdehyde (MDA).
5
 Environmental exposure to smog, cigarette smoke, and motor  
vehicle exhaust are potential sources for formaldehyde, acetaldehyde, and acrolein, 
2 
Table 1 Common sources of aldehydes. 
Endogenous Source Aldehyde 
Lipid peroxidation 4-hydroxynonenal, malondialdehyde, hexanal 
Dopamine catabolism 3-4-Dihydroxyphenylacetaldehyde 
GABA metabolism succinic semialdehyde 
Serotonin metabolism 4-hydroxyindoleacetaldehyde 
Putrescine catabolism γ-amino butyraldehyde 
Vitamin A metabolism retinaldehyde 
Carbohydrate metabolism glyceralehyde, glycolaldehyde, glyoxal 
  Exogenous Source Aldehyde 
Ethanol acetaldehyde 
Foods citral, benzaldehyde, crotonaldehyde 
Combustion formaldehyde, acetaldehyde, acrolein 
Cigarettes  γ-3-pyridyl-γ-methylbutyraldehyde 
 
 
amongst other aldehydes.
6
 Aldehydes are also used or produced in various industrial 
applications including the production of resins, polyurethane, and polyester plastics. Each 
of these sources can contribute to the aldehydic load within the body. Highly reactive and 
electrophilic carbonyl groups in aldehydes can form adducts with various 
macromolecules including proteins, nucleic acids, and glutathione. Unlike reactive 
oxygen species and free radicals, aldehydes have relatively long lifespans and once 
formed, can react with both nearby cellular components and targets some distance away 
via diffusion or molecular transport.
5
 Aldehydes can form a covalent adduct with proteins 
either by formation of a Schiff base via the ε-amino of lysine or by a Michael addition to 
cysteine, histidine, or lysine residues in a process called protein carbonylation.
7
 These 
reactions will typically result in a loss of function due to the importance of cysteine, 
histidine, and lysine in many enzyme catalytic mechanisms. Although moderate amounts 
3 
of carbonylation can be accommodated by cells, increasing amounts of carbonylation will 
eventually lead to protein dysfunction, cell death, and ultimately disease progression. It is 
important to note that protein carbonylation is elevated during oxidative stress and 
correspondingly a high proportion of carbonylated proteins are found in the 
mitochondria.
8
 Aldehydes have also been shown to inactivate antioxidant enzymes such 
as glutathione reductase and glutathione peroxidase by protein carbonylation, which as a 
consequence perpetuates oxidative stress in a positive feedback loop.
9, 10
 Aldehydes can 
also form adducts with DNA creating DNA-DNA and DNA-protein crosslinks, 
chromosomal aberrations, and other DNA damage.
11, 12
 
 
Cells have several mechanisms to alleviate aldehyde stress. Aldehydes can be reduced to 
an alcohol, oxidized to a carboxylic acid, or eliminated via interaction with glutathione. 
The main enzyme classes that reduce aldehydes to alcohols are alcohol dehydrogenases 
and aldo-keto reductases, and the main enzyme classes that oxidize aldehyde to 
carboxylic acids are aldehyde/xanthine oxidases and aldehyde dehydrogenases (Figure 
1). Alcohol dehydrogenases can catalyze the reversible reduction of aldehydes and 
ketones to an alcohol. The direction of this reaction is heavily dependent on the 
NAD
+
/NADH ratio. Oxidation of an alcohol to an aldehyde is the predominant reaction 
due to the normal 500:1 ratio of NAD
+
 to NADH found within cells.
13
 The aldo-keto 
reductase superfamily consists of 13 human enzymes and catalyzes the reversible 
reduction of a variety of aldehydes and ketones to their corresponding alcohols.
14
 
Aldehyde/xanthine oxidases catalyze the conversion of aromatic and heterocyclic 
aldehydes to their corresponding carboxylic acids.
15
 Aldehyde dehydrogenases catalyze 
4 
the NAD(P)
+
-dependent oxidation of an aldehyde to its corresponding carboxylic acid or 
ester CoA.
16
 Short-chain dehydrogenases/reductases compose a large subset of all 
dehydrogenases and can catalyze the NAD(P)H-dependent oxidation or reduction of 
aldehydes depending on the individual enzyme.
17
  Lipid peroxidation products can be 
eliminated via conjugation to glutathione via glutathione S-transferase.
18
 Although all of 
these enzymes contribute to the alleviation of the aldehydic load, aldehyde 
dehydrogenases are capable of oxidizing a variety of aromatic and aliphatic aldehydes 
and thus contribute to a wide range of physiological functions and generation of 
biological products. 
 
 
Figure 1 Aldehyde detoxification enzymes. 
5 
B. Aldehyde Dehydrogenase Superfamily   
The aldehyde dehydrogenase (ALDH) superfamily exists in all three taxonomic domains, 
Archaea, Eubacteria, and Eukarya, highlighting the important role that these enzymes 
have had throughout evolution.
19
 A nomenclature system based on sequence alignments 
and evolutionary relationships was established in 1999 and is used primarily in Eukarya 
(Figure 2).
20
 By convention members of different ALDH families have less than 40% 
protein sequence identity, while members of the same subfamily have more than 60% 
protein sequence identity. Due to the extensive 
amount of research done on ALDH2 in the field of 
ethanol metabolism prior to 1999, its name was 
grandfathered into the system, despite its amino 
acid sequence placing it in the ALDH1B 
subfamily. 
 
Currently there are 24 recognized ALDH families in eukaryotes; 11 of these families are 
represented in the human genome totaling 19 isoenzymes (Figure 3).
21
 ALDH 
isoenzymes differ in tissue location, subcellular location, substrate specificity, and 
structure. Many ALDH isoenzymes possess leader sequences that direct their 
translocation to specific subcellular locations.
22
 ALDHs have a variety of functions. 
ALDHs contribute to the synthesis of numerous important biological molecules including 
GABA, retinal, and tetrahydrofolate, and the removal of toxic aldehydes through their 
aldehyde oxidation activity.
23
 Physiological roles for ALDHs are not limited to enzymatic 
function. ALDHs in the eye function as structural proteins called crystallins which absorb 
6 
harmful UV light.
24
 ALDH16A1 may also serve as a structural protein as it lacks a 
functional nucleophile in its active site.
25
 A summary of the 19 ALDH isoenzymes is 
shown in Table 2.  
 
 
 
Figure 3 Phylogenetic tree for the human ALDH superfamily. 
Dendrogram of the 19 human ALDH members. Branch lengths depict degree of 
evolutionary divergence between isoenzymes.
26
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Human ALDHs are associated with a number of diseases due to their involvement in a 
variety of physiological processes (Table 2). Mutations in multiple ALDHs (ALDH1A1, 
ALDH1A2, ALDH1A3, ALDH1B1, ALDH1L1, ALDH2, and ALDH3A1) are associated 
with cancer, and overexpression of ALDH1A1 and ALDH3A1 in cancer is linked to poor 
prognosis and decreased efficacy of certain chemotherapeutics, including 
cyclophosphamide.
23, 27
 Aldh1a1
-/-
 and Aldh3a1
-/-
 single knockout mice as well as 
Aldh1a1
-/-
 Aldh3a1
-/-
 double knockout mice develop cataracts prematurely as ALDH1A1 
and ALDH3A1 both protect ocular tissue from UV radiation.
28
 The ALDH1A subfamily 
is significantly involved in retinoic acid signaling and mutations in these genes are often 
detrimental to embryogenesis and can lead to spina bifida.
23, 29
 ALDH1A1 and ALDH2 
have been linked to neurodegenerative diseases due to their involvement in dopamine 
metabolism.
30
 ALDH1B1 has been shown to be important in beta cell development; 
mutations may contribute to the eventual development of diabetes.
31
  
 
ALDH3A2 metabolizes the oxidization of fatty aldehydes and mutations are associated 
with Sjögren-Larssson Syndrome, an autosomal recessive disorder that leads to skin, 
cognitive, and neurological defects.
32
 A single nucleotide polymorphism in ALDH3B1 
has been linked to the development of paranoid schizophrenia.
33
 ALDH4A1 is involved 
in proline degradation and mutations in this gene lead to Type II hyperprolinemia 
characterized by seizures and mental retardation.
34
 ALDH5A1 is involved in the 
metabolism of the neurotransmitter GABA; mutations lead to γ-hydroxybutyric acidura 
characterized by neurological and cognitive defects.
35
 ALDH6A1 is the only known 
CoA-dependent human ALDH and this enzyme catalyzes the conversion of malonate 
10 
semialdehyde and methymalonate semialdehyde to acetyl-CoA and propionyl-CoA, 
respectively, in valine and pyrimidine catabolism.
36
 Mutations in the ALDH6A1 gene 
lead to a variety of metabolic abnormalities, which are typically accompanied by 
psychomotor delay.
37
 ALDH7A1 catalyzes the oxidation of α-aminoadipic semialdehyde 
during lysine metabolism; mutations are linked to pyridoxine-dependent epilepsy which 
causes severe seizures during infancy and early childhood.
38
 ALDH16A1 is unique 
amongst the human ALDH enzymes as the active site lacks key catalytic residues. 
Although the enzyme does not have aldehyde oxidation activity, ALDH16A1 may act as 
a binding partner to other proteins and has been linked to gout.
25
 ALDH18A1 catalyzes 
the reduction of glutamate to ∆-pyrroline-5-carboxylate during the de novo synthesis of 
the amino acids proline and arginine.
39
 Mutations in the ALDH18A1 gene result in 
various metabolic and neurologic abnormalities characterized by cataract formation, 
neurodegeneration, and connective tissue disorders.
40
 
 
The primary function for ALDH enzymes is aldehyde oxidation. Sequence alignment of 
145 ALDHs indicated that there is a small number of residues conserved in catalytically 
active enzymes, which include the catalytic cysteine and residues involved in cofactor 
binding.
41
 The reaction mechanism for aldehyde oxidation by ALDH isoenzymes is 
shown in Figure 4A. The process begins with binding of the cofactor NAD(P)
+
 in the 
Rossmann fold of the enzyme.
42, 43
 NAD(P)
+
 can adopt multiple conformations when 
bound to ALDHs (Figure 5).
44, 45
 Cys302 is the active site nucleophile and Glu268 acts 
as a general base (numbering based on mature ALDH2 sequence).
46, 47
 Cys302 is 
activated either directly by Glu268 or by a hydroxyl ion generated by Glu268 to perform 
11 
a nucleophilic attack on the carbonyl carbon of the aldehyde which yields the formation 
of a thioacyl-enzyme intermediate and hydride transfer to NAD(P)
+
. Glu268 then 
activates a water molecule that performs a nucleophilic attack on the carbonyl carbon of 
the thioacyl-enzyme intermediate which, after rearrangement, yields the reduced cofactor 
NAD(P)H and carboxylic acid product. The reduced cofactor is thought to be released 
after the carboxylic acid.
48
 Due to structural differences, the rate limiting step differs 
between enzymes. For example, the rate limiting step is cofactor dissociation for the 
ALDH1A subfamily, deacylation for ALDH2, and hydride transfer for ALDH3A1.
49-51
 
Many ALDHs, including ALDH2, also have a NAD(P)
+
-independent esterase activity 
which uses the same active site residues and is the same reaction that hydrolyzes the 
thioacyl-enyzme intermediate to regenerate the free enzyme (Figure 4B).
52, 53
  
 
Figure 4 Catalytic mechanisms for ALDH isoenzymes. 
Aldehyde oxidation (A) requires cofactor NAD
+
, while ester hydrolysis (B) does not. 
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Figure 5 Multiple conformations of cofactor bound to ALDH isoenzymes.  
NAD
+
 (black) and NADH (cyan) bound to human ALDH2 (purple) and NADP
+
 (yellow) 
bound to glyceraldehyde 3-phosphate dehydrogenase (E250A) from Streptococcus 
mutans (green). PDB codes 1O00, 1O02, 1O04, 2QE0. 
 
 
 
However, the presence of cofactor can stimulate esterase activity by either enhancing the 
nucleophilicity of Cys302 or increasing the frequency of productive encounters with 
Cys302.
54, 55
 Cofactor’s effect on esterase activity is due in part to the shape of the active 
site. Mammalian ALDHs function as either dimers or tetramers, with each monomer 
containing a catalytic domain, a cofactor binding domain (Rossman fold), and an 
oligomerization domain (Figure 6A & B).
56
 The active site of ALDH enzymes contains a 
tunnel where the cofactor binding site is located on one end, with the substrate site at the 
other end of the tunnel and the catalytic cysteine situated in the middle (Figure 6C). The 
ALDHs have evolved to recognize different aldehyde substrates due to differences in the 
size and shape of their respective binding site.
56, 57
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Figure 6 Structural characteristics of ALDH isoenzymes. 
(A) Ribbon diagram of the ALDH2 monomer. (B) Ribbon diagram of ALDH2 
homotetramer with each monomer colored individually. (C) Surface representation of 
tunnel connecting cofactor binding site and catalytic site of ALDH1A1. Region of 
catalytic cysteine colored in yellow. NADH (black) bound to cofactor binding site. (PDB 
Code 4WB9). 
 
C. Aldehyde Dehydrogenase 1/2 Family   
The aldehyde dehydrogenase 1/2 family in humans consists of seven isoenzymes: 
ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, ALDH1L1, and ALDH1L2. 
These enzymes are present among different tissues, and each can have variable 
expression patterns, along with oxidizing a variety of aldehydes. Thus the ALDHs have a 
diverse set of physiological functions.  
14 
The ALDH1A subfamily consists of the cytosolic ALDH1A1, ALDH1A2, and 
ALDH1A3 that share ~70% sequence identity. Each of the three isoenzymes can 
facilitate oxidation of retinal to retinoic acid (RA), though the substrate specificity for 
each of these enzymes differs. ALDH1A1 catalyzes the oxidation of all-trans-,9-cis-, and 
13-cis-retinal with Km values ranging from 2 – 6 µM.
58
 ALDH1A2 and ALDH1A3 prefer 
the all-trans isomer, but also can utilize the cis-isomers as substrates.
23, 59
 The RA 
products can then act on other cells in an endocrine or paracrine manner.
60
 Once in the 
nucleus of the target cell, the RA products then bind to retinoic acid (RAR) and retinoic 
X receptors (RXR) (Figure 7). Both RAR and RXR are type II nuclear receptors and as 
such are retained in the nucleus regardless of the presence or absence of ligand. RA 
products will bind to heterodimers of RAR and RXR, which interact with the retinoic 
acid response element (RARE), a specific DNA sequence in the promoter region of the 
target gene to regulate gene expression and cellular phenotype. RXRs also can form 
heterodimers with other nuclear receptors such as thyroid hormone receptors and 
peroxisomal proliferator activated receptors. Retinoid metabolism and signaling are 
involved in embryogenesis, cell cycle control, cell growth, and differentiation.
61, 62
 
Dysregulation of these functions has been linked to obesity, diabetes, cardiovascular 
disease, cancer, and fetal/birth defects.
61, 62
 Whereas Aldh1a1 knockout mice are viable, 
both Aldh1a2 and Aldh1a3 knockout mice do not produce viable animals, suggesting that 
ALDH1A2 and ALDH1A3 are more involved in embryogenesis and tissue patterning.
63
 
Aldh1a2
-/-
 knockout mice are characterized by defects in heart development and death at 
midgestation, while Aldh1a3
-/-
 knockout mice are characterized by nasal and ocular  
15 
 
Figure 7 Retinoic acid signaling pathway. 
Retinol (vitamin A) is oxided by retinal dehydrogenases (RDH) to produce retinal, which 
is further oxidized by ALDH1A enzymes to produce retinoic acid (RA). RA then diffuses 
into the nucleus and initiates transcription of target genes which contain RARE elements 
in their target genes via activation of heterodimers of RAR and RXR. Depending on the 
cellular context, the increased transcription can lead to differentiation, apoptososis, or cell 
cycle arrest. Adapted from Marcato et al.
64
  
 
 
defects, similar to RAR mutants, which lead to respiratory failure shortly after birth. 
65, 66
 
Although Aldh1a1
-/-
 knockout mice are viable, the absence of Aldh1a1 activity results in 
reduced retinoic acid synthesis later in life.
67
 Mouse Aldh1a7, an ALDH1A1 paralog not 
found in humans, may partially rescue the Aldh1a1
-/-
 knockout mouse phenotype.
68
 
Aldh1a1
-/-
 knockout mice are also resistant to diet-induced obesity and insulin 
resistance.
69
 Based on in vitro studies, the major enzyme expressed during adipogenesis 
is ALDH1A1, compared to other vitamin-A metabolizing enzymes.
70
 The increased 
levels of retinaldehyde in the Aldh1a1
-/-
 knockout mice could have several beneficial 
effects in regards to adipogenesis. Retinaldehyde decreased fat levels and increased 
16 
insulin sensitivity in an obese mouse model.
69
 Retinaldehyde is also an inhibitor of 
peroxisomal proliferator activated receptors gamma (PPARγ), a transcription factor 
heavily involved in adipogenesis, and in activation of RXRs.
69
 There is a fourth possible 
retinal dehydrogenase in humans, ALDH8A1, though it shares only 40% sequence 
identity with ALDH1A1 and is most similar to bacterial tryptophan metabolism 
enzymes.
71
 
 
The function of ALDH1A1 is not limited to retinoid signaling. ALDH1A1 can also 
catalyze the oxidation of 3-4-dihydroxyphenylacetaldehyde (DOPAL) to 3-4-
dihydroxyphenylacetic acid (DOPAC) and the conversion of acetaldehyde to acetic acid 
during ethanol metabolism; both of these processes will be discussed further in later 
sections concerning neurodegenerative diseases and alcohol abuse.
30, 72
 ALDH1A1, as 
well as ALDH1A2 and ALDH1A3, contribute to the oxidation of lipid peroxidation 
products such as 4-hydroxynonenal (4-HNE), malondialdehyde (MDA), and hexanal.
23
 
ALDH1A1 will act as corneal and lens crystallins in eye tissue alongside other ALDHs.
73
 
In this role, ALDH1A1 protects the tissue from ultraviolet radiation damage and 
contributes to transparent and refractive properties of the eye tissue.
74
 ALDH1A1 can 
also bind to androgens, thyroid hormone, and cholesterol and interact with drugs like 
quinolone and flavopiridol.
21, 75, 76
  
 
ALDH2 is a mitochondrial homotetramer with 67% sequence identity to the ALDH1A 
subfamily. ALDH2 is ubiquitously expressed, though the expression levels are variable 
with the heart, liver, kidney, lung, and brain having high levels.
23
 ALDH2 is well-known 
17 
for being the primary enzyme responsible for the catalysis of acetaldehyde to acetic acid 
during ethanol metabolism.
77
 ALDH2 is involved in the metabolism of lipid peroxidation 
derived aldehydes, including 4-HNE and MDA.
16
 ALDH2 also can oxidize DOPAL to 
DOPAC and bioactivate nitroglycerin.
30, 78
 The various functions of ALDH2 and how 
each contribute to various disease states will be discussed further in later sections. 
 
ALDH1B1 is a mitochondrial homotetramer that has 72% sequence identity to ALDH2. 
Although the physiological function of ALDH1B1 is still unknown, ALDH1B1 was 
reported to oxidize acetaldehyde with a low KM (55 µM) suggesting that this enzyme has 
a role in ethanol metabolism, especially when ALDH2 activity is low.
79
 ALDH1B1 can 
also catalyze the oxidation of 4-HNE and MDA, like ALDH2 and members of the 
ALDH1A subfamily.
79
 Aldh1b1
-/-
 knockout mice displayed increased blood acetaldehyde 
levels post ethanol consumption and higher fasted blood glucose levels.
80
 ALDH1B1 also 
influences the transition from the pancreas endocrine progenitor to the mature beta cell.
31
 
Expression of ALDH1B1 was found to be increased in pancreatic adenocarcinoma, 
suggesting that this enzyme contributes to cancer proliferation.
81
 Furthermore, 
ALDH1B1 has been proposed to be  a biomarker for colon cancer.
82
 ALDH1B1 may 
contribute to colon cancer growth by helping regulate the Wnt/β-catenin, Notch, and 
phosphoinositide 3-kinase (PI3K)/Akt signaling pathways.
83
  
 
ALDH1L1 and ALDH1L2 are two enzymes that are the fusion of two or more distinct 
activities. Both are included in the aldehyde dehydrogenase 1/2 family due to the 
sequence similarity in their aldehyde dehydrogenase domains. ALDH1L1 is a multi-
18 
domain protein with two distinct catalytic domains, an amino-terminal formyl transferase 
domain and a carboxy-terminal aldehyde dehydrogenase domain.
84
 Unlike the 
aforementioned members of the ALDH1/2 family, ALDH1L1 prefers NADP
+
 as a 
substrate.
85
 ALDH1L1, also known as 10-formyltetrahydrofoltate (10-FTHF) 
dehydrogenase, catalyzes the conversion of 10-FTHF to tetrahydrofolate (THF).
86
 THF, 
the major metabolite of dietary folate, is important in one-carbon metabolism and 10-
FTHF is involved in purine synthesis and may have an impact on DNA replication and 
repair.
87
 ALDH1L1 is suggested to have a role in cancer development. Overexpression of 
ALDH1L1 in multiple cancer cell lines suppressed cellular proliferation and increased 
cytotoxicity.
88
 In keeping with the idea that ALDH1L1 may suppress cancer progression, 
ALDH1L1 was reported to be downregulated in human liver, lung, prostrate, pancreas, 
and ovarian cancers.
88
 ALDH1L1 also contributes to alleviating methanol toxicity. 
Methanol is metabolized in the liver by two steps to form formate, with formaldehyde as 
the intermediate product.
89
 Accumulation of formate is believed to cause the majority of 
the deleterious effects associated with methanol poisoning.
89
 Formate is oxidized to 
carbon dioxide by first being condensed with THF to form 10-FTHF by 
methylenetetrahydrofolate dehydrogenase. 10-FTHF is then converted to THF by 
ALDH1L1 to regenerate THF while releasing carbon dioxide as a product.
23
  
 
ALDH1L2 shares 72% sequence identity with ALDH1L1 and has a mitochondrial leader 
sequence. ALD1L2 is also a multi-domain protein containing an amino-terminal formyl-
trans-N-formyl transferase domain, a formyltransferase domain in the middle, and a 
carboxy-terminal aldehyde dehydrogenase domain.
26
 The physiological function of 
19 
ALDH1L2 is still unknown, though it likely relates to folate metabolism in the 
mitochondria.  
 
D. ALDH1A1, Cancer, and Cancer Stem Cells 
According to the National Cancer Institute, approximately 40% of all men and women 
will be diagnosed with cancer at some point in their lifetime and national expenditures for 
cancer care totaled nearly $125 billion in 2010 and could reach $150 billion by 2020. The 
longstanding model for development of solid tumors stated that these tissues are 
heterogeneous and most, if not all, cells are capable of metastasis. The cancer stem cell 
model states that a small subset of cells, called cancer stem cells, have the ability to 
proliferate extensively while the vast majority of cancer cells are differentiated and have 
a limited capacity for tumor formation.
90
  Cancer stem cells, also known as tumor-
initiating cells, are defined by enhanced tumorigenicity and the capacity for self-
renewal/differentiation.
64
 Some cancer stem cells may arise from dedifferentiation of 
differentiated cancer cells through the right combination of transcription factors.
91
 
Though the idea that cancer may originate from a small population of cells with stem 
cell-like properties was first proposed in the 19
th
 century, cancer stem cells were first 
identified in1994 in acute myeloid leukemia.
92, 93
 Cancer stem cells were later found in 
solid tumors as well.
94
 Signal transduction pathways involved in oncogenesis, including 
those featuring Notch, Sonic hedgehog, and Wnt, are also important for stem cell self-
renewal.
95
 Many current cancer treatments utilize a stochastic approach, targeting all cells 
to minimize tumor size. However, if cancer stem cells are inherently resistant to 
chemotherapeutics and represent a minority of the total tumor cell population, then 
20 
cancer stem cells may still be present in the smaller tumor and be able to regenerate the 
cancer. This may explain why tumor regression does not correlate with increases in 
patient survival in clinical trials for advanced cancers.
96
 Specifically targeting cancer 
stem cells, while sparing normal stem cells, is one way to treat cancer by eliminating the 
tumor-initiating cell population. 
 
ALDHs are widely used to identify cancer stem cells and ALDH1A1 is considered a 
cancer stem cell marker.
97
 ALDH1A1 is overexpressed in many cancers, including lung, 
ovarian, stomach, and breast, and is associated with poor outcomes in many cases.
98
 The 
manner in which ALDH1A1 contributes to stem cell biology is not well understood as 
Aldh1a1 deficient mice have no noticeable disruption in stem cell function, though 
ALDH1A1’s function in retinoid metabolism is worth noting as retinoids effect cellular 
differentiation.
99
 Retinoic signaling has been shown to play a major role in embryonic 
stem cells and cancer cells.
100, 101
 Breast cancer stem cells treated with the non-selective 
ALDH inhibitor diethylaminobenzaldehyde showed enrichment with genes involved with 
cell self-renewal while cancer stem cells treated with all-trans retinoic acid had similar 
gene expression profiles as differentiated cancer cells.
102
 ALDH enzymes also protect 
cancer stem cells from reactive oxygen species generated under oxidative stress 
conditions.
103
 Tumor cells can undergo hypoxia and a loss of oxygen tension, giving rise 
to reactive oxygen species and oxidative stress.
104
 ALDH1A1, alongside ALDH3A1, also 
helps provide cellular protection from cytotoxic drugs; for example, both ALDH1A1 and 
ALDH3A1 can convert cyclophosphamide, an alkylating agent, to the inactive product 
carboxyphosphamide.
105, 106
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Mammary cancer cells form spheroids in 3D culture that are rich in progenitor cells and 
have metastatic capacity.
107
 These spheroids are rich in ALDH1A1 enzymatic activity 
and have been associated with poorer clinical outcome in breast cancer cases.
108
 Other 
cancers, including prostrate and ovarian, have also been shown to form spheroids.
109, 110
  
The ability of ovarian cancer cells to form spheroids may facilitate metastases and enable 
cancers to survive chemotherapy.
111
 Spheroids grown in 3D culture in vitro represent a 
better approximation of tumor cells in vivo compared to cancer cells grown in monolayer 
culture.
111
 Ovarian cancer spheroids have elevated ALDH1A1 enzyme activity, but not 
elevated transcription of other ALDHs linked to cancer, such as ALDH1A2, ALDH1A3, 
ALDH2, and ALDH3A1.
111
 Although the exact role of ALDH1A1 in cancer stem cell 
viability is unclear, it is not related to its role in retinoic acid signaling as these cells 
remain dedifferentiated. The elevation in ALDH1A1 activity may be in response to 
increased oxidative stress due to decreased oxygen tension in the interior of the 
spheroids.  
 
The role of ALDH1A1 in cancer stem cells may also be related to various signaling 
pathways. Inhibition of the β-catenin/Wnt pathway prevented multicellular aggregation in 
cancer spheroids. Given that ALDH1A1 is important for spheroid formation, and 
ALDH1A1 is a direct target of the transcription factor β-catenin, it is likely that this 
ALDH enzyme functions downstream of the β-catenin/Wnt pathway in cancer 
progression.
111
 Likewise activation of β-catenin and dysregulation of the Wnt pathway is 
common in cancer.
112
 ALDH1A1 expression and activity have also been connected to the 
Hippo pathway. Inhibition of ALDH1A1 led to growth attenuation of MDA-MB-468 
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cells in 3D culture as well as a decrease in the activity of YAP, a transcription factor in 
the Hippo pathway.
113
 Overexpression of YAP is also correlated with an increase in 
ALDH1A1 expression in MDA-MB-468 cells. YAP binds to TEAD elements in 
promoters of target genes and the ALDH1A1 promoter region contains a TEAD 
element.
113
 Compounds which selectively inhibit ALDH1A1 could be used as chemical 
probes to better understand the role ALDH1A1 plays in cancer stem cell function and 
tumor metastasis. 
 
E. ALDH2, ALDH2*2, and Alcohol-Induced Pathophysiology 
Aldehyde dehydrogenase 2 (ALDH2) is a mitochondrial enzyme that adopts a 
homotetramer structure. The enzyme functions more accurately as a dimer of dimers as 
only two of the catalytic sites seem to be active at any given time.
114
 An N-terminal 
mitochondrial targeting sequence (MTS) directs the protein to the mitochondria, where 
upon entrance of the enzyme into this organelle, the sequence is cleaved to form the 
mature protein.
22
 ALDH2 is the primary ALDH isoenzyme responsible for the oxidation 
of acetaldehyde (Km < 1 µM) during ethanol metabolism.
115
 Other isoenzymes, such as 
ALDH1A1 and ALDH1B1, can also contribute to the oxidation of acetaldehyde, 
especially in the case of the ALDH2*2 variant.
72, 116
 The ALDH2*2 allele is among the 
most prevalent human enzyme deficiencies, affecting ~540 million people worldwide.
117
 
Found in ~40% of individuals of East Asian descent, the ALDH2*2 allele can be traced 
back to the Han Chinese population over 2000 years ago.
118, 119
 Individuals with the 
ALDH2*2 allele will develop nausea, dizziness, headaches, and vasodilation (facial 
flushing), also known as alcohol flush reaction, after ethanol consumption due to 
23 
decreased ALDH2 enzymatic activity.
117
 The lower activity is caused by a single 
nucleotide change (G→A) that results in an E487K substitution (E504K with the MTS 
included), which causes a 10-fold reduction in kcat and increases the Km for coenzyme 
(NAD
+
) above physiological levels.
120
 Glu487 appears to maintain a stable structural 
scaffold and facilitate catalysis by connecting the cofactor binding domain and substrate 
binding domains in ALDH2 through interactions with other residues in the enzyme.
121
 
The crystal structure of ALDH2*2 lacks density for the helix αG of the Rossman fold and 
a loop in the active site (Figure 8A).
122
 The ALDH2*2 allele is dominant as ALDH2*2 
homozygotes have little to no ALDH2 activity and ALDH2 activity in heterozygotes is 
severely reduced.
123
 If one ALDH2*2 monomer is present in the tetrameric unit the entire 
tetrameric unit is enzymatically compromised due to Glu487 being located along the 
interface between monomers (Figure 8B).
121
 The ALDH2*2 allele is associated with a 
lower risk of alcoholism due in part to the adverse physiological response upon alcohol 
consumption.
124
 However, societal pressure can overcome this reduced risk.
125, 126
 
ALDH2*2 has also been associated with alcoholic liver disease and cirrhosis.
127
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Figure 8 Structure of ALDH2 versus ALDH2*2. 
(A) Monomer of ALDH2 (orange) vs ALDH2*2 (cyan). The E487K substitution is 
located in the oligomerization domain. (B) E487K substitution is located at the dimer 
interface. The E487K residue (yellow/mauve) faces the active-site loop of the 
neighboring monomer (orange/cyan). PDB Code 1O02 and 1ZUM. 
 
Approximately 16 million people in the United States have an Alcohol Use Disorder, 
which encompasses both alcohol abuse and alcohol dependence, and the misuse of 
alcohol costs the United States over $200 billion annually.
128, 129
 Ethanol was classified as 
a group 1 carcinogen by the International Agency for Research on Cancer in 2007; 
however, acetaldehyde is most likely the chemical species that leads to malignancy.
130
 
Blood acetaldehyde levels are significantly higher after moderate ethanol consumption in 
ALDH2-deficient individuals.
131-133
 Acetaldehyde can form DNA-DNA and DNA-
protein crosslinks.
134, 135
 Multiple DNA adducts have been seen in human cells and in 
mice exposed to acetaldehyde.
136, 137
 DNA damage contributing to the development of 
upper aerodigestive track (UADT) cancers is most likely caused by acetaldehydes.
138, 139
 
ALDH2*2 carriers have an increased risk of developing UADT cancers and have 
increased levels of acetaldehyde-induced DNA damage.
140, 141
 Acetaldehyde-induced 
DNA damage may also contribute to the diseases phenotypes seen in Fetal Alcohol 
25 
Syndrome and Fanconi Anemia.
142, 143
 Fanconi Anemia (FA) is caused by a recessive 
mutation to one of many identified FA genes, including FANCD2, which function to 
repair DNA cross-links.
144
 A maternal functional copy of ALDH2 was necessary to 
counteract aldehyde toxicity in the development of Aldh2
-/-
 Fancd2
-/-
 double knockout 
mouse embryos. Aldh2
-/-
 Fancd2
-/-
 mouse embryos were also sensitive to developmental 
deformities in the uterus when the mothers were exposed to ethanol.
143
 Interestingly, the 
most common cancers in adult FA patients are UADT or head and neck cancers.
145
 
 
Accumulation of acetaldehyde can also lead to cardiotoxicity. Acetaldehyde can cause 
cardiac hypertrophy and contractile dysfunction.
146, 147
 Adult mice overexpressing 
ALDH2 are more resistant to acute ethanol cardiotoxicity.
148
 ALDH2 confers cardiac 
protection partly through the regulation of Akt and AMPK signaling and mTOR and 
thereby autophagic flux.
149
 Pharmacological activation of ALDH2 reversed ethanol-
induced cardiac defects and apoptosis, as did the AMPK inhibitor compound C.
150
 
Although an excess amount of alcohol will lead to cardiotoxicity, a moderate amount of 
ethanol will activate ALDH2 through phosphorylation by PKCε to alleviate cardiac 
stress.
151
 
 
F. ALDH2 and Cardiovascular Disease 
Cardiovascular diseases are a major cause of morbidity and mortality worldwide. The 
role of ALDH2 in cardiac health is not limited to acetaldehyde-induced cardiotoxicity. 
Other cardiotoxic aldehydes originating from reactive oxygen species-induced stress can 
also cause myocardial dysfunction.
152, 153
 Reactive oxygen species generate lipid 
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peroxidation products, such as 4-hydroxynonenal (4-HNE) and malondialdehyde, which 
will form adducts with various proteins, which can culminate in cardiac dysfunction.
154
 4-
HNE modified proteins are elevated in patients with hypertrophic and dilated 
cardiomyopathy, hypertension, and peripheral artery disease.
155
 Mice overexpressing 
ALDH2*2 exhibited impaired mitochondrial bioenergetics and elevated levels of 4-HNE 
protein adducts.
156
 Overexpression of ALDH2 prevented 4-HNE protein adduct 
formation and alleviated myocardial damage from ischemia reperfusion.
157
 However, 4-
HNE can form adducts with ALDH2 itself and inactivate the enzyme.
158
 Pharmacological 
activation of ALDH2 offers cardioprotection from lipid peroxidation aldehydes, and can 
prevent the inactivation of the enzyme by 4-HNE.
151
 Specifically, Alda-1, an ALDH2 
activator, decreased ischemic damage after a myocardial infarction.
151
 The ALDH2*2 
allele is also a risk factor for acute coronary syndrome and hypertension.
159-161
  
 
Nitroglycerin (GTN) is often used to treat angina and heart failure.
162
 GTN works by 
increasing blood flow to the heart through the vasodilator nitric oxide (NO).
163
 ALDH2 is 
the key enzyme that catalyzes the bioactivation of GTN to 1,2-glyceryl dinitrite (1,2-
GDN).
164
 The proposed mechanism involves the formation a thionitrate on the catalytic 
cysteine (Cys302) and release of 1,2-GDN. A disulfide bond is then formed between 
Cys302 and one of the two adjacent cysteine residues and nitrite is released.
165
 Sustained 
GTN treatment leads to tolerance and is associated with pro-oxidant effects and 
endothelial dysfunction.
166, 167
 Tolerance is mainly mediated by the inability of ALDH2 
to catalyze the conversion of GTN to 1,2-GDN and nitrite, which is then further reduced 
to NO.
168
 Acetaldehyde, acting as a competitive substrate, and the ALDH2 inhibitor 
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daidzin both suppress the bioactivation of GTN by ALDH2.
169, 170
 Individuals with the 
ALDH2*2 mutation have a reduced vasodilatory response to GTN and have higher 
incidences of GTN tolerance.
171, 172
 Pharmacological activation of ALDH2 or ALDH2*2 
by Alda-1 did not increase the denitration and bioactivation of GTN, though Alda-1 does 
help prevent the development of GTN tolerance by preventing inactivation by produced 
NO, similar to the protection from 4-HNE adduct formation by Alda-1.
173, 174
 
 
G. ALDH1A1, ALDH2, and Neurological Disease 
Multiple neurological diseases are highlighted by the accumulation of aldehyde products 
and mitochondrial dysfunction.
175, 176
 Two of these diseases are Parkinson’s disease (PD) 
and Alzheimer’s disease. PD is a neurodegenerative disorder that is found in 1% of the 
population over 65 years old and is characterized by the intracellular aggregation of α-
synuclein in so-called Lewy bodies and the loss of dopaminergic neurons in the 
substantia nigra.
177, 178
 3,4-dihydroxyphenylacetaldehyde (DOPAL) has been identified as 
a neurotoxin that will induce Parkinsonism.
179
 DOPAL is a metabolic product of the 
neurotransmitter dopamine formed via monoamine oxidase. Most DOPAL is then 
converted by an ALDH to the carboxylic acid 3,4-dihydrophenylacetic acid (DOPAC), 
though reduction to the alcohol 3,4-dihydrophenylethanol (DOPET) also occurs. One of 
the most prevalent treatments for PD is the dopamine precursor levodopa, which serves to 
increase the levels of dopamine in the brain, but does not halt the progression of the 
disease.
180
 Accumulation of the lipid peroxidation product 4-HNE can also contribute to 
the symptoms of PD.
181
 Both ALDH1A1 and ALDH2 have been linked to the 
progression of PD. Although DOPAL is a substrate, DOPAL can also inhibit ALDH1A1 
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and ALDH2 decreasing its own catabolism.
30, 182, 183
 4-HNE also will inhibit the 
conversion of DOPAL to DOPAC, presumably by covalently binding to ALDH2.
183
 
Exposure to benomyl, a fungicide and potent inhibitor of ALDH2, led to increased 
development of PD in factory workers.
184
 ALDH1A1 mRNA and protein have been 
found to be downregulated in PD as well.
185, 186
 Double knockout mice of ALDH1A1 and 
ALDH2 have elevated levels of DOPAL and 4-HNE, loss of dopaminergic neurons in the 
substantia nigra, and age-dependent deficits in motor performance.
187
 As neither single 
knockout develop substantial neurodegeneration, it remains unclear which enzyme, 
ALDH1A1 or ALDH2, is the major contributor to the metabolism of dopamine with 
regards to PD.
188, 189
 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by a 
loss of cortical neurons that results in the onset of dementia.
190
 By 2050 it is estimated 
that 13.2 million Americans will have the disease.
191
 4-HNE accumulates in the 
hippocampus of patients with early AD.
192
 4-HNE adduct formation is believed to 
contribute to amyloid plague formation seen in the later stages of AD.
193
 Individuals with 
the ALDH2*2 allele have a higher incidence of AD.
194
 
195
 Likely this is due to the 
decreased ability of the ALDH2*2 allele to oxidize 4-HNE and prevent adduct 
formation.
196
 ALDH2*2 transgenic mice developed age-related neuronal loss associated 
with memory loss, premature aging, and shortened life span.
197
 Pharmacological 
activation of ALDH2 prevented amyloid β peptide-induced impairment of angiogenesis 
in cultured endothelial cells.
198
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Dopamine metabolism, and thereby ALDH2, is also linked to the development of 
addiction. Addictive drugs lead to increased dopamine release in the nucleus 
accumbens.
199
 Inhibition of ALDH2 led to a decrease in cocaine seeking behavior in rats 
through the formation of tetrahydropapaveroline (THP).
200
 Inhibition of ALDH2 causes 
an increase in DOPAL concentration leading to the condensation of DOPAL and 
dopamine to form THP. THP selectively inhibits tyrosine hydroxylase to reduce 
dopamine signaling via a negative-feedback loop.
200
 Inhibition of ALDH2 has also been 
found to prevent alcohol-induced dopamine release.
201
 
 
H. ALDH1/2 Activators and Inhibitors 
Activating and/or inhibiting the function of various ALDHs are potential 
pharmacological approaches for the treatment of human pathologies. Development of 
inhibitors/activators has so far been primarily limited to three isoenzymes: ALDH1A1, 
ALDH2, and ALDH3A1.
56
 However, selectivity amongst the ALDH isoenzymes has 
remained a challenge. One of the first clinical applications for the inhibition of ALDHs 
was the inhibition of ALDH2 as an antidipsotropic therapy.
202
 ALDH2 inhibitors, like 
daidzin and disulfiram, cause a buildup in acetaldehyde during consumption of alcohol, 
which yields symptoms similar to the alcohol flush reaction seen with ALDH2*2. As a 
consequence the drug decreases the consumption of alcohol. Daidzin is an isoflavone 
derived from the kudzu plant and is a 100x more potent inhibitor of ALDH2 compared to 
ALDH1A1.
203, 204
 Analogs of daidzin including CVT-10216 are being developed to be 
more selective for ALDH2.
201
 However, the effects of daidzin and its analogs on the 
activity of ALDH1A2, ALDH1A3, and ALDH1B1 are understudied. Disulfiram, itself, 
30 
inhibits ALDH1A1 more strongly than ALDH2, although its in vivo metabolites are more 
potent towards ALDH2.
205, 206
 Disulfiram will also inhibit ALDH1B1.
79
 The sulfur atoms 
in disulfiram also make it a copper chelator and disulfiram will inhibit tyrosine β-
hydroxylase and other copper-dependent enzymes.
207
 Disulfiram has been used to treat 
cocaine addiction by decreasing norepinephrine release and as an anti-cancer agent 
utilizing some of these non-ALDH effects.
208, 209
 Several ALDH inhibitors act as slow 
substrates for the target enzyme(s). Citral is a volatile α,β-unsaturated aldehyde found 
naturally in herbs and citrus fruits. Citral can inhibit multiple ALDH isoenzymes by 
acting as a slow substrate thereby inhibiting the oxidation of faster substrates.
56
 4-
(Diethylamino)benzaldehyde, the control inhibitor for the Aldeflour Assay for cancer 
stem cell detection, also acts as a slow substrate for many of the ALDH isoenzymes and 
as a mechanism-based inhibitor for others.
210
 Gosspyl is also an aldehyde, though its 
inhibition does not seem to be derived from being a slow substrate. Gosspyl is more 
selective for ALDH3A1 compared to the ALDH1/2 family, and also inhibits other 
NAD(P)
+
-dependent enzymes. Gosspyl most likely interacts with the cofactor binding 
sites of these enzymes.
211
 Many biocides, including benomyl, also inhibit ALDH 
isoenzymes.
212
 WIN 18446, a potent inhibitor of spermatogenesis, has been found to 
inhibit the activity of ALDH1A2; the activity of WIN 18446 on other ALDH isoenzymes 
remains unknown.
213
 
 
Although achieving selectivity for one of the ALDHs is challenging, a few compounds 
have recently been discovered via high throughput screening (HTS). HTS has been used 
to develop more selective ALDH3A1 inhibitors in use for sensitizing ALDH3A1-positive 
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cancer cells to oxazaphosphorine treatment.
214, 215
 HTS has also been used to discover 
ALDH1A1 inhibitors such as CM037. CM037, a benzothienopyrimidinone with an ester 
side chain, is a selective inhibitor of ALDH1A1 by competitively interfering with 
propionaldehyde binding to the enzyme. CM037 takes advantage of Gly458 in the active 
site of ALDH1A1, which is a much larger residue in the other catalytically active ALDH 
isoenzymes.
216
 However, as an ester, CM037 will most likely be hydrolyzed quickly in 
vivo. 
 
Activators can also serve as chemical probes to elucidate the function of the various 
ALDH isoenzymes. There are only a few small molecular activators of ALDHs compared 
to the large number of ALDH inhibitors. Tamoxifen has been found to induce the activity 
of ALDH1A1 by 2-fold.
217
 Alda-1 also activates ALDH2 by 2-fold and can prevent 
inactivation by toxic aldehyde substrates, such as 4-HNE, increasing protection from 
oxidative stress.
151
 Alda-1 can also act as a chemical chaperone and restore ALDH2*2 to 
near-normal function.
55
 Alda-1 may also activate ALDH1A1 activity after DOPAL-
induced inactivation.
218
 Alda-1 and its analogs are being further developed as ALDH2-
selective activators; however, this compound series has solubility issues which most 
likely will preclude its use in a clinical setting.  
 
I. Hypothesis and Approach 
Even though ALDH2 has been targeted for the treatment of alcoholism since 1948, there 
remains a lack of selective ALDH2 inhibitors.
219
 Additionally, the selective ALDH2 
activator Alda-1 has solubility issues which limit its use. We hypothesized that the unique 
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topologies of the substrate sites in ALDH isoenzymes will permit the discovery and 
optimization of inhibitors that can specifically probe the function of selected ALDHs, in 
this case ALDH2. These selective compounds could then be used to better elucidate the 
individual function of ALDH2 in both health and disease. 
 
As selective compounds for ALDH1A1 and ALDH3A1 have been previously found 
through in vitro high-throughput screening (HTS), we used an in vitro HTS to identify 
potential selective inhibitors for ALDH2.
214, 220
 Normally ALDH activity is measured by 
oxidation of aldehyde substrate by measuring the production of NADH at 340 nm on a 
spectrophotomer (ε = 6220 M-1 cm-1). However, this assay is not ideal for high-
throughput screening of chemical libraries as many compounds have similar absorption 
properties as NADH and provide interference. Although measuring the fluorescence of 
NADH is one alternative option, we utilized the  sterase activity of ALDH2 to perform a 
high-throughput screen. In this reaction para-nitrophenylacetate is hydrolyzed to para-
nitrophenol, the production of which is measured spectrophotometrically at 405 nm. Both 
the dehydrogenase and esterase reactions utilize the same critical residues, with Glu268 
acting as a general base to activate Cys302, thus any compound that modulates esterase 
activity will also likely modulate aldehyde oxidation activity.
56
. The esterase reaction 
also has the advantage of being NAD
+
-independent, meaning compounds which bind to 
the coenzyme-binding site are less likely to be identified. 
 
Once compounds were identified via the HTS, several additional approaches were used to 
characterize and determine compound selectivity: (1) steady state competition assays to 
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determine mode of inhibition, (2) X-ray crystallographic studies of compound-inhibitor 
complexes, (3) structure activity relationship experiments to help determine the basis of 
selectivity and potency, and (4) cell culture experiments to determine effects of 
compound on proliferation of cancer cells (Figure 9). 
 
 
 
 
Figure 9 Research approach to identifying compounds that alter ALDH activity. 
Hit compounds are identified through high-throughput screening. Hit compounds are then 
analyzed via enzyme kinetic, X-crystallographic, and cell culture experiments to form 
structure activity relationships to guide the basis for improved compounds. These 
improved compounds can then be considered new hit compounds and be analyzed using 
the same means. Eventually, the improved compounds would be tested in an animal 
model for effects in vivo.  
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II. Materials and Methods 
A. Materials 
Chemicals and reagents used for protein expression and purification, enzyme kinetics, X-
ray crystallography, and cell culture were purchased from Sigma-Aldrich (St. Louis, MO) 
unless otherwise noted. Compounds were purchased from ChemDiv Corporation (San 
Diego, CA), ChemBridge Corporation (San Diego, CA), InterBioScreen Limited 
(Moscow, Russia), Life Chemicals (Burlington, ON), and Princeton BioMolecular 
Research Inc. (Princeton, NJ). Dithiothreitol (DTT) was purchased from GoldBio (St. 
Louis, MO). Sitting drop plates for crystallography were purchased from Charles Supper 
Co (Natick, MA). 
 
B. Methods 
1. Production and Purification of ALDH Isoenzymes 
The full-length cDNA for human ALDH2 was generously provided by Dr. Henry 
Weiner, Purdue University, in a pT7-7 vector and used to transform E. coli BL21 cells for 
subsequent expression and purification of the enzyme.
221
 The general protocol for the 
production and purification for ALDH1A1, ALDH1A2, and ALDH2 has been published 
previously.
214, 221
 Specifically, a single transformed BL21 colony was transferred to 10 
mL 2xTY broth containing 100 µg/mL ampicillin and grown overnight in culture at 37°C 
while shaking. A 5 mL aliquot of the overnight culture was used to inoculate 100 mL 
2xTY containing 100 µg/mL ampicillin the next morning and was grown at 37°C while 
shaking. After 1-2 hours 10 mL of the 100 mL was added to 8 x 1L 2xTY broth 
containing 100 µg/mL ampicillin and incubated at 37°C with shaking at 200 rpm. Once 
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the culture reached an optical density of 0.6 to 0.8 at 600 nm, isopropyl-β-D-
thiogalactopyranoside was added to a final concentration of 100 µM to induce the 
synthesis of the enzyme. Cultures were incubated overnight at 16°C while shaking at 200 
rpm and then collected via centrifugation, flash frozen in liquid nitrogen and then stored 
at -80°C. Cell pellets were thawed at room temperature and then resuspended in lysis 
buffer (10 mM sodium phosphate (NaPi) pH 7.0, 2 mM EDTA, 1 mM benzamidine, 1 
mM DTT). Cells were lysed via three passages through a microfluidizer (DivTech 
Equipment). Cell lysate was clarified by centrifugation at 35,000 rpm for 25 min at 4°C 
(Beckman-Coulter Optima L-90K Ultracentrifuge, Ti-45 Rotor). The clarified lysate was 
dialyzed against 2 x 4 L changes of lysis buffer at 4°C each for at least 5 hours. The 
lysate was then loaded onto a DEAE-sepharose column and eluted using gradient from 0-
250 mM NaCl in lysis buffer. The eluted fractions from the DEAE-sepharose column 
were analyzed by SDS gel and an activity assay to confirm the presence of active 
enzyme. In the activity assay 20 µL of the eluted fraction was added to saturating 
amounts of NAD
+
 (75 mM) and propionaldehyde (10 mM) in 100 mM sodium 
pyrophosphate buffer, pH 9.5 and activity determined by measuring the change in 
absorbance at λ=340 nm due to NADH production. Fractions containing protein were 
pooled and dialyzed into 4L 4-hydroxyacetophenone (4-HAP) column buffer (20 mM 
NaPi pH 7.5, 1 mM EDTA, 50 mM NaCl, 1 mM DTT) overnight. The dialyzed enzyme 
was then loaded onto the 4-HAP column and eluted in a single step with approximately 
75 mL of 4-HAP buffer containing 10 mM 4-hydroxyacetophenone. The protein 
preparations were then dialyzed exhaustively against 10 mM ACES, pH 6.6 with 1 mM 
DTT at 4°C. Enzyme was concentrated to 5-10 mg/mL using Amicon Ultra Centrifugal 
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Devices (Millipore Corp, Bedford, MA). Prior to storage, the protein concentration was 
measured using the BioRad Protein Assay (BioRad Laboratories, Hercules, CA) and its 
aldehyde oxidation activity measured using saturating amounts of NAD
+
 and 
propionaldehyde to determine specific activity. An 8 L preparation generated ~150 mg 
ALDH1A1, ~60 mg ALDH2, or ~35 mg ALDH1A2. Aliquots were flash frozen in liquid 
nitrogen and stored at -80°C. Portions of the ALDH1A1 and ALDH2 preparation were 
stored at -20°C in a 50% (v/v) solution with glycerol for future crystallization. Prior to 
crystallization set-up the enzyme was dialyzed against 3 X 4L changes of 10 mM sodium 
ACES, pH 6.6 with 1 mM DTT at 4°C for at least 5 hours each. All solutions were 
sparged with helium to remove dissolved oxygen before use to help prevent oxidation of 
cysteine residues in addition to the DTT already present. 
 
ALDH1B1 and ALDH3A1 were produced and purified as previously described.
214, 222
 
ALDH3A1 was purified and provided by Dr. Bibek Parajuli and a portion of ALDH1B1 
used was purified and provided by Lanmin Zhai. The full length cDNA for human 
ALDH4A1 and ALDH5A1 was generously provided by Dr. Daria Mochly-Rosen and the 
carboxyl terminus of rat ALDH1L1 was generously provided by Dr. Sergey Krupenko in 
the pRSET expression plasmid. ALDH1L1 was expressed and purified as previously 
described for ALDH3A1 with the following modifications: 1) the medium contained 100 
µg/mL ampicillin, 2) cells were lysed via passage through a microfluidizer, 3) the second 
passage through a Q-sepharose column was not included. The purification of ALDH4A1 
and ALDH5A1 followed the same protocol as ALDH1L1.
210
 The purification of 
ALDH1A3 followed one of two protocols. The first is consistent with that of ALDH1A1, 
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ALDH1A2, and ALDH2 and produced very small amounts of ALDH1A3.
214
 Dr. Jaume 
Ferres (Barcelona, Spain) generously provided a His-tagged construct for full length 
ALDH1A3. The His-tagged ALDH1A3 was produced and purified by a single passage 
through a nickel-NTA column similar to the purification of ALDH4A1, ALDH5A1, and 
ALDH1L1 and yielded ~120 mg per 8 L culture for enzymatic study. 
 
2. Esterase High-Throughput Screen 
The high-throughput screen (HTS) was performed using a reaction where para-
nitrophenyl acetate (pNPA) is hydrolyzed to form para-nitrophenol and acetic acid. The 
esterase assay was used for screening as it is cofactor independent and the spectral 
properties of para-nitrophenol do not overlap with the absorbance characteristics of the 
majority of compounds within the tested libraries. The substrate was prepared by adding 
0.0725 g of pNPA to 6 mL of 100% DMSO. This mixture was added slowly to 94 mL of 
water with continuous stirring for a final concentration of 4 mM pNPA in 6% (v/v) 
DMSO. Screens were completed with two different libraries at the Indiana University 
Chemical Genomics Core Facility in 384-well, clear-bottomed plates. Screen 1 consisted 
of 63,000 compounds from ChemDiv Corporation (San Diego, CA) and utilized 75 nM 
ALDH2, 0.8 mM pNPA, 10 µM library compound, 2% DMSO, and 25 mM HEPES 
buffer, pH 7.5 for a final reaction volume of 50 µL. Screen 2 consisted of 50,000 
compounds from ChemBridge Corporation (San Diego, CA) and utilized 75 nM ALDH2, 
1.6 mM pNPA, 10 µM library compound, 3.2% DMSO, and 25 mM HEPES buffer, pH 
7.5 also in a final volume of 50 µL. The concentration of library compound is an 
approximation based upon the average mass of the compounds in the entire library. The 
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production of para-nitrophenol was monitored by measuring the increase in absorbance at 
λ=405 nm (molar extinction coefficient of 18,000 M-1 cm-1) on a Spectromax Plus 384 
plate reader for 10 minutes. Additional wells on each plate either had an inhibitor control 
or no compound present to determine the normal rate. The inhibitor control for Screen 1 
was 100 µM daidzin. Screen 2 used 1 µM 2,3,5-trimethyl-6-propyl-7H-furo[3,2-
g]chromen-7-one (2P3), an inhibitor discovered in the Screen 1. A multichannel pipet 
was used to add either 20µL of 2% DMSO solution, 20µL of 250 µM daidzin in 2% 
DMSO, or 20µL of 2.5 µM 2P3 in 2% DMSO to their respective control column. The 
Genesis (Tecan) Workstation TeMO with a 96-channel pipetting head was used to make 
all subsequent reagent additions. The rate of reaction was used to determine a ratio to 
control for each compound with control being the average of the rates for the positive 
control (wells with no compound) on that compound’s plate (n=16): 
Equation 1: 𝑅𝑎𝑡𝑖𝑜 𝑡𝑜 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 =
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑤𝑖𝑡ℎ 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑟𝑎𝑡𝑒 𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 
Compounds which had ratios to control less than 0.60 (>40% inhibition) were considered 
inhibitors and those with a value greater than 1.25 (1.25-fold activation) were considered 
activators in Screen 1. Compounds which met these selection criteria were rescreened for 
validation using the same protocol. Selection criteria for Screen 2 was greater than 40% 
inhibition or 2-fold activation in both the primary and secondary screens.  
 
A Z’-factor was calculated for the screening conditions prior to completion of each HTS 
by comparing the values of ALDH2 plus/minus the control inhibitor (each n=384) under 
the conditions of that particular HTS using the following formula: 
Equation 2: 𝑍′-𝑓𝑎𝑐𝑡𝑜𝑟 = 1 −
3(𝛿𝑝+𝛿𝑛)
|𝜇𝑝−𝜇𝑛|
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where µp and δp are the mean and standard deviation of the control reaction and µn and δn 
are the mean and standard deviation of the inhibition reaction. A Z’-factor was also 
calculated using 1 mM NAD
+
 as an esterase activator during Screen 2. A Z’-factor 
between 0.5 and 1.0 indicates a good assay that is statistically strong enough to detect 
inhibitors and/or activators. Confirmed chemical hits that were commercially available 
were purchased from ChemDiv Corporation (San Diego, CA), ChemBridge Corporation 
(San Diego, CA), Interbioscreen Limited (Moscow, Russia), Life Chemicals (Burlington, 
ON) or Princeton BioMolecular Research Inc. (Princeton, NJ) to determine their effect on 
aldehyde oxidation. 
 
3. Aldehyde Oxidation Activity Assays for ALDH Isoenzymes 
The effect on the aldehyde oxidation activity of ALDH isoenzymes by the hit compounds 
from the screens was determined by measuring the formation of NAD(P)H 
spectrophotometrically at λ=340 nm (molar extinction coefficient of 6220 M-1 cm-1 ) on a 
Beckman DU-640 spectrophotometer using purified recombinant enzyme. Compounds 
were initially tested for their effect against ALDH1A1, ALDH2, and ALDH3A1. For 
ALDH1A1 and ALDH2, the reaction contained 100-200 nM enzyme, 200 µM NAD
+
, 
100 µM propionaldehyde, and 1% DMSO in 50 mM BES, pH 7.5 at room temperature. 
For ALDH3A1, the reaction contained 20-25 nM enzyme, 300 µM NADP
+
, 300 µM 
benzaldehyde, and 1% DMSO in 100 mM NaPi buffer, pH 7.5. The reaction was initiated 
by addition of aldehyde substrate after a 2 min pre-incubation of enzyme, coenzyme, and 
compound. Compounds were initially screened at a concentration of 10 µM. 
Measurements at higher concentrations of compound were occasionally used to aid in 
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interpretation of data. Compounds that were potentially selective for ALDH1A1 and/or 
ALDH2 were then tested with other ALDH isoenzymes. For ALDH1A2 and ALDH1A3, 
the reaction contained 100-400 nM enzyme, 200 µM NAD
+
, 100 µM propionaldehyde, 
and 1% DMSO. The assay for ALDH1B1 used 500 µM NAD
+
 and 200 µM 
propionaldehyde. For ALDH4A1 the assay included 500 µM NAD
+
 and 20 mM 
propionaldehyde. For ALDH5A1 the assay included 200 µM NAD
+
 and 2 mM 
propionaldehyde. For rat ALDH1L1 the assay included 500 µM NADP
+
 and 4 mM 
propionaldehyde. The assay components for the selectivity assays were designed to 
provide the maximal stringency toward ALDH2, such that the substrate concentration 
utilized was >500-fold above KM for ALDH2 while keeping below 15-fold over Km for 
the other isoenzymes. All reactions were initiated with the addition of aldehyde substrate 
after a 2 min pre-incubation period. EC50 values for aldehyde oxidation were calculated 
by varying the concentration of compound from 0 - 100 µM for compounds which 
showed greater than 50% activation/inhibition at 10 µM concentration of compound. 
Assay parameters for EC50 calculation were the same as for the initial selectivity screen, 
with the use of 500 µM acetaldehyde as an additional aldehyde substrate for AC50 
calculations with ALDH2. Data were fit to the four parameter EC50 equation using 
SigmaPlot (v12): 
Equation 3: 𝑦 = 𝑚𝑖𝑛 +
(𝑚𝑎𝑥−𝑚𝑖𝑛)
1+(
𝑥
𝐸𝐶50
)
−𝐻𝑖𝑙𝑙𝑆𝑙𝑜𝑝𝑒 
where y is the rate of activity and x is the concentration of compound. The values 
represent the mean/SEM of three independent experiments, with each experiment n = 3. 
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Thirty-four additional psoralen and coumarin derivatives were ordered from ChemDiv 
Corporation (San Diego, CA) and ChemBridge Corporation (San Diego, CA) to build 
structure-activity relationships for the hit compounds. Analogs were selected as a 
representative sample of the 600+ commercially available compounds which had >95% 
structure similarity. EC50 values for aldehyde oxidation for these compounds were 
calculated using the same protocol as the initial hit compounds. Data were fit to the four 
parameter EC50 equation (Equation 3) using SigmaPlot (v12) . The values represent the 
mean/SEM of three independent experiments, with each experiment n=3.  
 
4. Steady-State Kinetic Characterization with ALDH1A1 and ALDH2 
The mode of inhibition of the compounds was characterized by steady state kinetics 
through covariance of compound and either aldehyde substrate or coenzyme 
concentration. The secondary substrate was kept at a saturating amount. The mode of 
inhibition towards NAD
+
 binding with ALDH1A1 was determined by covarying inhibitor 
and coenzyme concentrations at a fixed aldehyde substrate concentration. Dehydrogenase 
activity was measured spectrophotometrically by measuring the formation of NADH at 
340 nm (molar extinction coefficient of 6200 M
-1
 cm
-1
) on a Beckman DU-640 
spectrophotomer for 3 min. The assay included 100-200 nM ALDH1A1, 20-200 µM 
NAD
+
, 1 mM propionaldehyde, and 1% DMSO in 25 mM BES buffer, pH 7.5. The 
reaction was initiated by the addition of propionaldehyde after a 2 minute pre-incubation 
with enzyme, NAD
+
, and compound. The mode of inhibition towards NAD
+
 binding with 
ALDH2 was determined in a similar fashion. The activity of ALDH2 was determined in a 
reaction containing 100-200 nM ALDH2, 15-400 µM NAD
+
, 1 mM propionaldehyde, 
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and 1% DMSO in 25 mM BES buffer, pH 7.5. All data were fit to the tight binding or 
single substrate-single inhibitor non-linear velocity expressions for competitive, non-
competitive, mixed type non-competitive, and uncompetitive inhibiton using SigmaPlot 
(v12, Enzyme Kinetics Module). Lineweaver-Burk plots were generated using SigmaPlot 
(v12) to better visualize the model fit. The appropriate model was selected through 
analysis of goodness-of fit. Values shown represent the mean/SEM of three independent 
experiments (each n=3).  
 
The mode of inhibition towards aldehyde substrate binding for ALDH2 was measured via 
fluorescence spectroscopy. The KM of ALDH2 for propionaldehyde (<1 µM) is so low 
that measurement of activity at near KM concentrations is nearly impossible by 
measurement of absorbance.
223
 Utilizing the fluorescent characteristics of NADH allowed 
for the measurement of these activities. A standard curve of the fluorescence of NADH 
from 10 nM to 3000 nM was first measured for use in converting the arbitrary 
fluorescence units into the amount of NADH produced during the experiment. The KM 
values for propionaldehyde and cofactor NAD
+
 for ALDH2 were then determined for 
ALDH2 using the fluorescence assay as these values may differ from those obtained 
using the absorbance assay. Dehydrogenase activity was measured by monitored the 
fluorescence of NADH at λ = 470 nm after excitation at λ = 320 nm for 2 min measuring 
every five seconds. Reactions for KM calculations contained 5 nM ALDH2 in 100 mM 
NaPi, pH 7.0 in a reaction volume of 3 mL. The KM for NAD
+
 was determined by 
plotting increasing concentrations of NAD
+
 (10-400 µM) versus the velocity of the 
reaction with a saturating amount of propionaldehyde (1 µM). The KM for 
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propionaldehyde was determined by plotting increasing concentrations of 
propionaldehyde (50-750 nM) versus the velocity of the reaction with a saturating 
amount of NAD
+
 (400 µM). Data were plotted using the Simple Ligand Binding Toolbox 
in SigmaPlot (v12) and the values represent the mean/SEM of a single experiment (n=3). 
Steady-state kinetics were used to measure the mode of inhibition towards 
propionaldehyde binding in ALDH2. Assay solutions included 5 nM ALDH2, 400 µM 
NAD
+
, 75-600 nM propionaldehyde, 0.2% DMSO, and 0-80 nM inhibitor in 100 mM 
NaPi, pH 7.0. Due to low concentrations of substrate used in the assay, all reagents were 
filtered to remove additional aldehyde contaminants. All data were fit to the tight binding 
non-linear velocity expressions for competitive, non-competitive, mixed-type non-
competitive and uncompetitive inhibition using SigmaPlot (v12, Enzyme Kinetics 
Module) to evaluate goodness of fit. Lineweaver-Burk plots were generate using 
SigmaPlot (v12) to better visualize the mode of inhibition. All data represent the 
mean/SEM of the four independent experiments (n=4) of duplicate assays at each 
concentration. 
 
5. Characterization of 2BS4’s Inhibition of ALDH2 
IC50 curves were measured for the inhibition of ALDH2 by 2BS4 utilizing different 
incubation times. The rate of aldehyde oxidation was determined by measuring the 
formation of NADH spectrophotometrically at λ=340 nm (molar extinction coefficient of 
6220 M
-1
 cm
-1
) on a Beckman DU-640 spectrophotometer using purified recombinant 
enzyme. The assay solutions included 150 nM ALDH2, 200 µM NAD
+
, 100 µM 
propionaldehyde, 0 – 50 µM 2BS4, and 1% DMSO in 25 mM BES buffer, pH 7.5. The 
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reaction was initiated by addition of enzyme to coenzyme, compound, and substrate (0 
min incubation) or by addition of aldehyde substrate after either a 2 or 10 min pre- 
incubation of enzyme, coenzyme, and compound. Data were fit to the four parameter  
EC50 equation (Equation 3) using SigmaPlot (v12). Values represent the mean/SEM of 
one experiment with three replicates for each data point (n=3). 
 
The interaction of the compound 2BS4 with ALDH2 was characterized further by 
incubating 2BS4 with ALDH2 before the addition of NAD
+
 and aldehyde substrate. 
Dehydrogenase activity was measured spectrophotometrically by determining the 
formation of NADH at 340 nm (molar extinction coefficient of 6200 M
-1
 cm
-1
) using a 
Beckman DU-640 spectrophotomer for 3 min. The assay included 200 nM ALDH2, 0.3 
µM or 1.5 µM 2BS4, 200 µM NAD
+
, 1 mM propionaldehyde, and 1% DMSO in 25 mM 
BES buffer, pH 7.5. ALDH2 was incubated with either 3 µM or 15 µM 2BS4 in 10% 
DMSO for various time periods before subsequent 10-fold dilution into the assay. After 
dilution of the ALDH2/2BS4 solution, the reaction was initiated by the addition of 
propionaldehyde after 2 minute incubation with ALDH2/2BS4 and NAD
+
. The 
measurement at zero hour(s) incubation was taken by diluting the enzyme-compound 
mixture immediately after addition of compound. Each data point represents the average 
of two measurements. (n=2) 
 
6. Crystallization of ALDH1A1 and ALDH2 Complexes 
The general crystallization conditions for both ALDH1A1 and ALDH2 have been 
reported previously.
44, 220
 Crystals of ALDH1A1 were grown by equilibrating 3 mg/mL 
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ALDH1A1 with 100 mM sodium BisTris, pH 6.2 – 6.6, 9 – 11% PEG 3350, 200 mM 
NaCl, and 5 mM YbCl3 using the sitting drop method with 500 µL mother liquor. Drop 
composition consisted of 2 – 4 µL protein mixed with 2 – 4 µL crystallization solution. 
The drop was then mixed by agitation. Crystallization was allowed to proceed at 22°C in 
an incubation chamber and crystals grew in 1 – 2 weeks. BUC11 and BUC22 complexes 
were prepared by growing ALDH1A1 crystals in the presence of 200 µM compound and 
2% (v/v) DMSO (co-crystallization). Compound was first added to the protein solution 
before mixing with the crystallization solution. The BUC25 complex was prepared by 
soaking an apo-ALDH1A1 crystal overnight with crystallization solution containing 500 
µM BUC25 with 2% (v/v) DMSO. All ALDH1A1 crystals were cryoprotected for flash-
freezing by adding 20% (v/v) ethylene glycol to the final crystallization solution. Crystals 
were frozen in a liquid nitrogen cryostream and were tested on the home source Bruker 
D8 system for diffraction quality. Crystals with good diffraction were stored in liquid 
nitrogen until data collection at a synchrotron source. 
 
Crystals of the 2P3-ALDH2 complex were grown by equilibrating 8 mg/mL ALDH2 and 
200 µM 2P3 in 2% DMSO with 100 mM sodium ACES, pH 6.4, 100 mM guanidine-
HCl, 10 mM MgCl2, 4 mM dithiothreitol, and 18% PEG 6000 using the sitting drop 
method with 500 µL mother liquor. Crystal plates were set up in a glove box then 
transferred to an incubation chamber at 22°C for crystal growth. Crystals typically grew 
in 1 – 2 weeks. Crystals were cryoprotected for flash-freezing by adding 18% (v/v) 
ethylene glycol to the final crystallization solution. Crystals were frozen in a liquid 
nitrogen cryostream and were tested on the home source Bruker D8 system for diffraction 
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quality. Crystals with good diffraction were stored in liquid nitrogen until data collection 
at a synchrotron source.  
 
Diffraction data was collected at Beamline 19-ID operated by the Structural Biology 
Consortium at the Advanced Photon Source, Argonne National Laboratory, Chicago, IL. 
Diffraction data was indexed, integrated, and scaled using the HKL2000 or HKL3000 
program suites.
224
 The CCP4 program suite was used for molecular replacement and 
refinement.
225
 The human apo-ALDH2 structure (PDB Code 3N80) was used as a model 
for ALDH2 and the human apo-ALDH1A1 structure (PDB Code 4WJ9) was used as a 
model for ALDH1A1. Molecular replacement was necessary as both the ALDH1A1-
BUC22 and ALDH2-2P3 complexes were obtained in orientations and/or space groups 
not seen previously using the same conditions. The ALDH2-2P3 complex was obtained 
in the previously seen P212121 crystal lattice but with different unit cell dimensions. The 
ALDH1A1-BUC22 complex was obtained in a previously unseen P1 crystal lattice that 
contained two tetramers in the asymmetric unit. Previous ALDH1A1 structures, and the 
ALDH1A1-BUC25 and ALDH1A1-BUC11 structures, were obtained in a P422 space 
group with a single monomer in the asymmetric unit. The molecular graphics application 
Coot was used for model building.
226
 Ligand maps were generated using Sketcher 
(CCP4) to use for refinement. The TLSMD (Translation/Libration/Screw Motion 
Determination) server was used to determine dynamic properties of ALDH1A1.
227, 228
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7. Cellular Effect of the Coumarin Derivative BUC22 
MDA-MB-468 (ER-/PR-/HER-) breast cancer cells were generously provided by Dr. 
Clark Wells (IUSM). MDA-MB-468 cells were cultured in 1X DMEM (Cellgro, 
Mediatech Inc, Manassa, VA) supplemented with 10% fetal bovine serum (FBS) (Cell 
Applications Inc, San Diego, CA) and 100 Units/mL penicillin and 100 µg/mL 
streptomycin (P/S)(Lona, Walkersville, MD). Cells were passaged after every 80-90% 
confluence (normally every 3-4 days). 
 
The 3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide (MTT) assay was 
used to measure the proliferative potential of cancer cells after treatment with BUC22. 
Cells were plated at 5000 cells/well density in 96-well clear bottom cell culture plates on 
40 µL ~7mg/mL Matrigel Matrix Basement Membrane (Corning, Bedford, MA). Cells 
were treated starting on the day of plating (Day 1) by adding compound in 0.5% (v/v) 
DMSO to 200 µL DMEM supplemented with FBS and P/S. One set of wells contained 
Matrigel alone and one set contained cells on Matrigel, both in compound-free media. 
Media was changed on Day 3 and Day 5. On Day 6 media was aspirated and 0.1 mL of 
MTT (0.5 mg/mL in PBS) was added to each well followed by incubation for 4 hours at 
37°C to allow for reduction of MTT to its formazan. After reduction 100 µL 0.05N HCl 
in 10% SDS was added to each well followed by incubation for 4 hours at 37°C to lyse 
the cells. After the second incubation the absorbance of each well was measured at λ=595 
nm. Each experiment had three duplicate wells of each condition. Values were 
normalized by subtracting absorbance values of wells which contained only Matrigel. 
Data represent the mean/SEM of three independent experiments, each n=3.  
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III. Results 
A. Esterase High-Throughput Screen for ALDH2 Modulators 
Two high-throughput screens (HTS) were performed to identify activators and inhibitors 
of ALDH2 as measured by its in vitro esterase activity. Screen 1 consisted of 63,000 
compounds from ChemDiv Corporation (San Diego, CA) and Screen 2 consisted of 
50,000 compounds from ChemBridge Corporation (San Diego, CA). Both the esterase 
hydrolysis and aldehyde oxidation reactions use the same catalytic residues. The use of 
the esterase reaction for screening purposes has two advantages over the aldehyde 
oxidation reaction. First, interference from compounds with overlapping UV absorbance 
characteristics with NADH is minimized. Secondly, the esterase reaction does not require 
NAD
+
 and thus the esterase reaction limits identification of compounds that interfere with 
cofactor binding. The cofactor binding site is highly conserved among ALDH 
isoenzymes, thus compounds that bind in the cofactor binding site are less likely to be 
selective and options to achieve selectivity are limited.  
 
1. Z’-factor Calculation 
A Z’-factor score was calculated prior to the start of each HTS due to the use of different 
control inhibitors for each screen. A Z’-factor between 0.5 and 1.0 indicates an excellent 
assay to distinguish differences in activity from control reactions, i.e. determine 
activators and inhibitors. The Z’-factor for Screen 1 comparing ALDH2 activity 
with/without inhibitor (100 µM Daidzin) was 0.60 (Figure 10). During the course of 
Screen 1 a more potent ALDH2 inhibitor was discovered and used as the control inhibitor 
for Screen 2. The Z’-factor for Screen 2 comparing ALDH2 activity with/without 
49 
inhibitor (1 µM 2P3) was 0.50 (Figure 11). The better inhibitor did not improve the Z
’
-
factor. For Screen 2 a Z’-factor comparing ALDH2 activity with/without activator (1 mM 
NAD) was also calculated and found to be 0.46 (Figure 11). Based off the Z’-factor both 
screens were excellent at discovering inhibitors of ALDH2 esterase activity. The Z’-
factor for Screen 2 for determination of activation was nearly excellent as well. Although 
increasing the amount of enzyme could have made it easier to distinguish activators, it 
also would have made it more likely that any activator would not follow a linear rate for 
the duration of the screen. The lower Z’-factor for Screen 2 may be due to higher 
background due to the use of twice as much substrate.  
 
Figure 10 Z’-factor determination for Screen 1. 
Each point represents the rate of change in absorbance at 405 nm of a reaction. The x-
axis is the column (1-24) on the 384-well plate. The blue data points correspond to the 
enzyme + substrate (ES) control (mean=4.02); the red is enzyme + substrate + inhibitor 
(ESI) (mean=1.54); the black is the no enzyme blank control (mean=0.380). The lines 
represent 3x standard deviation from ES mean (blue), ESI mean (red), and blank (black). 
Each condition performed on a separate plate with n=384. 
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Figure 11 Z’-factor determination for Screen 2. 
Each point represents the rate of change in absorbance at 405 nm of a reaction. The x-
axis is the column (1-24) on the 384-well plate. The blue data points represent the 
enzyme + substrate (ES) control (mean=3.50); the red is enzyme + substrate + inhibitor 
(ESI) (mean=1.23); the green in enzyme + substrate + activator (ESA); the black in no 
enzyme blank control (mean=0.990).  The lines represent 3x standard deviation from ES 
mean (blue), ESI mean (red), ESA mean (green) and blank (black). Z’-factor for ESA vs 
ES shown in green and for ESI vs ES shown in red. Each condition performed on a 
separate plate with n=384. 
 
 
 
2. High-Throughput Screen Results 
The two libraries totaling over 110,000 compounds from ChemDiv and ChemBridge 
were screened using the esterase assay. Plates were acquired from the Indiana University 
Chemical Genomics Core with 20 µL of 25 µM of each compound, which was already 
present in the first 22 columns of each 384-well plate. Each plate also contained a control 
column with enzyme and substrate (ES control). The average of intra-plate ES control 
served as the basis to determine whether a compound modulated esterase activity. Each 
plate also contained an additional control column with enzyme and substrate and inhibitor 
to ensure significant inhibition could be measured on each plate. A representative plate is 
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shown in Figure 12. Selection criteria were initially set at either greater than 2-fold 
activation or less than 60% activity. Due to the lack of activators obtained from Screen 1, 
the selection threshold was lessened to 1.25-fold activation for only Screen 1. The 
primary screen of Screen 1 yielded a total of 1395 compounds and that of Screen 2 
yielded 536 compounds that were activators or inhibitors of ALDH2’s esterase activity. 
These 1931 compounds were then rescreened using the same assay parameters. Only 53 
compounds from Screen 1 and 14 compounds from Screen 2 met the threshold criteria in 
the secondary screen, meaning that over 95% of compounds did not meet the selection 
criteria a second time. Of the 67 compounds identified through the high-throughput 
screens, 59 were commercially available and purchased for further study. 
 
 
Figure 12 Example plate from Screen 1 for compounds that modify ALDH activity. 
Each point represent one well, with the x axis the column (1-24) on the plate and the y 
axis the rate of change in absorbance measured at λ=405 nm. Column 23 is the ESI 
control with a mean value of 1.78 (n=16). Column is the ES control with a mean value of 
4.93 (n=16). On this plate we identified one activator and fifteen inhibitors. 
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B. Hit Compound Validation and Initial Determination of Selectivity 
We were able to obtain 59 of the 67 compounds identified through the high-throughput 
screen. At this point we switched from monitoring the esterase function of aldehyde 
dehydrogenase to the aldehyde oxidation function in part to better evaluate how the 
compounds will modulate the complete catalytic mechanism of ALDHs. The effect of the 
hit compounds on the activity of ALDH1A1, ALDH2, and ALDH3A1 was tested as an 
initial determination of selectivity and potency.  Of the 59 compounds examined at 10 
µM concentration, 45 did not modulate the activity of ALDH2 more than 20% in either 
direction relative to control. Several of the 45 compounds which did not modulate 
ALDH2 activity influenced the activity of one or both of the ALDH1A1 and ALDH3A1 
enzymes by more than 20% (2CD12, 2BS2, 2BS6, 2P5, 2P7, 2P9, 2P11, 2P12, 2LC1, 
2F3, 2F8, 2F10, 2F11, and 2F12). Of the 14 compounds that did modulate ALDH2 
activity, several were determined to have low potency and/or selectivity based off the 
measurements at 10 µM concentration. 2C1 activated each enzyme ~1.2 fold at 10 µM 
concentration. 2CB4 inhibited all three isoenzymes greater than 80% and 2F13 inhibited 
all three around 50%. 2C2 inhibited ALDH1A1 activity much greater than ALDH2 
activity. Although 2CD4 inhibited the activity of ALDH2, the compound showed 
activation of ALDH1A1. 2CD5 showed some selectivity towards ALDH2, though the 
potency was low compared to other hit compounds. 2CB5, 2P2, and 2P4 were selected 
for further analysis due to their high potency towards ALDH2 (≥80% inhibition) and 
relative selectivity against ALDH1A1 and ALDH3A1 (Figure 13). However, additional 
batches of 2P2 ordered to continue enzymatic studies no longer inhibited ALDH2 at this 
concentration. The first batch of 2P2 may have had an additional contaminant leftover 
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from synthesis of the compound which enhanced ALDH2 inhibition; however, this could 
not be verified due to the exhausted supply of the initial stock. As a consequence, 2CB5 
and 2P4 were the two most promising remaining hit compounds. Both 2BS4 and 2LC2 
showed selectivity towards ALDH2 but contain a terminal methyl ester group; these 
potential esterase substrates were initially avoided, as inhibition could be lost or 
diminished after ester hydrolysis. 2BS4 was eventually included again due to its 
structural similarity to 2P4 and 2CB5. 2P3, which did not show the same level of 
selectivity towards ALDH2 as 2P4 and 2CB5 but had the highest potency, was also 
included due to the structural similarity. 
. 
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Figure 13 Effect on aldehyde oxidation of hit compounds from HTS. 
The activity of 59 compounds (10 µM) identified via HTS was tested on three ALDH 
isoenzymes. Average of at least two (n≥2) independent trials. 
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Figure 13 Continued Effect on aldehyde oxidation of hit compounds from HTS. 
The activity of 59 compounds (10 µM) identified via HTS was tested on three ALDH 
isoenzymes. Average of at least two (n≥2) independent trials. 
 
 
56 
 
Figure 13 Continued Effect on aldehyde oxidation of hit compounds from HTS. 
The activity of 59 compounds (10 µM) identified via HTS was tested on three ALDH 
isoenzymes. Average of at least two (n≥2) independent trials. 
 
 
 
 
The effect of the four compounds (2BS4, 2P3, 2P4, and 2CB5) on other ALDH 
isoenzymes was tested to generate a broader view of the compounds’ selectivity towards 
ALDH2 (Figure 14). The effect of 10 µM of each compound on the dehydrogenase 
activity of the other three ALDH1A/2 family members (ALDH1A2, ALDH1A3, and 
ALDH1B1) was determined, in parallel with assays of ALDH4A1, ALDH5A1, and 
ALDH1L1 (rat). Inhibition of the isoenzymes by the four compounds was limited to the 
ALDH1/2 family as the compounds did not modulate the activity of ALDH3A1, 
ALDH4A1, ALDH5A1, or ALDH1L1 (rat). Each compound showed the greatest amount 
of inhibition towards ALDH2 of the isoenzymes tested. For any particular ALDH1/2 
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enzyme, 2P3 inhibited the most, followed by 2CB5, then 2P4 at 10 µM. The inhibition 
profile for the four compounds was very similar between ALDH1A2, ALDH1A3, and 
ALDH1B1. 2BS4 only showed inhibition towards ALDH2 at this single concentration of 
compound. 
 
 
Figure 14 Effects of four aromatic lactones on activity of nine ALDH isoenzymes. 
Percent dehydrogenase activity for nine ALDH isoenzymes in the presence of 10 µM 
compound compared to control reaction with no compound present. Value is the average 
of at least three independent trials (n≥3) with standard error, except for the measurement 
of ALDH1B1 activity with 2P4 and ALDH1L1 activity with each compound (n=2). 
 
 
 
C. EC50 Determination of Hit Compounds 
1. Alda-1 Mimics 
Although no compounds from the HTS activated ALDH2’s oxidation of propionaldehyde 
by more than 20% at 10 µM concentration, three compounds (2CD11, 2CB8, and 2CB9) 
identified in the HTS were structurally similar to Alda-1 and thus were examined further 
(Figure 15).  Each share the benzodioxol group that in Alda-1 is bound within the 
substrate tunnel oriented towards Cys302. The three compounds were found to activate 
the oxidation of propionaldehyde by ALDH2 while having no effect on the activity of 
ALDH1B1, ALDH1A1, ALDH1A2, ALDH1A3, or ALDH3A1. Each of the compounds 
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had an AC50 equal to approximately 50-60 µM and activated the oxidation of 
propionaldehyde by at most 2-fold (Table 3). Each compound became insoluble in the 
assay solution between 200 and 500 µM; therefore solubility limits prevented a more 
accurate measurement of the AC50 for propionaldehyde oxidation by ALDH2. For 2CB8, 
full dose-response analysis could not be completed. The AC50 of ~60 µM is based off the 
assumption that the maximum activity would be near 2-fold if the curve could be 
completed.  
 
Figure 15 Three Alda-1 mimics identified via the HTS.  
Compounds share a benzodioxol group linked to a carboxamide through an isoxazole 
linker (shown in red). 
 
 
Since Alda-1 activated the oxidation of smaller substrates more effectively, we also 
tested the effect the three activators had on the oxidation of acetaldehyde by ALDH2. 
The three compounds had varying effects on acetaldehyde oxidation. 2CB9 was the most 
potent (AC50 = 9.6 ± 2.2 µM) but increased the maximum acetaldehyde oxidation activity 
the least (160 ± 4%). 2CD11 was the least potent (AC50 = 28 ± 5 µM) but increased the 
maximum acetaldehyde oxidation activity of ALDH2 the most (210 ± 9%) (Table 3). 
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The AC50 values for propionaldehyde and acetaldehyde oxidation with each compound 
are higher than those seen with Alda-1.
55
 For this reason, along with the solubility issues, 
these compounds were not further studied. 
 
Table 3 AC50 determination of Alda-1 mimics with ALDH2.  
Values are the mean of a single experiment of three independent measurements (n=3). 
Values for 2CB8 for propionaldehyde oxidation are approximated based off an 
incomplete curve using the assumption that binding behavior is consistent with the other 
compounds.  
Compound 
Aldehyde Substrate 
Acetaldehyde Propionaldehyde 
Max Activity AC50 (µM) Max Activity AC50 (µM) 
2CD11 210 ± 9% 28 ± 5 180 ± 11% 50 ± 16 
2CB8 200 ± 10% 14 ± 4 ~200% ~60 
2CB9 160 ± 4% 9.6 ± 2.2 200 ± 19% 61 ± 29 
 
 
 
 
2. Coumarin and Psoralen Derivatives, in Comparison to Daidzin 
The four compounds (2BS4, 2P3, 2P4, and 2CB5) are aromatic lactones (Figure 16). 
2P3, 2P4 and 2CB5 are psoralen derivatives and 2BS4 is a coumarin derivative. The 
differences between 2P3, 2P4, and 2CB5 lie in the presence and length of the various 
alkyl substituents attached to the aromatic substructure. 2BS4 contains an alkyl chain 
with a terminal methyl ester group bound to the psoralen substructure via an ether 
linkage. The ether oxygen is in the same relative position as the furan oxygen of 2P3, 
2P4, and 2CB5. 
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Figure 16 Four aromatic lactone inhibitors identified via the HTS. 
Compounds each share a coumarin aromatic structure with an oxygen atom bound to the 
benzyl ring. For 2CB5, 2P3, and 2P4; this takes the form of a psoralen aromatic structure.  
 
 
 
The IC50 values for daidzin for the ALDH1/2 family were measured to compare our 
results to compounds (including CVT-10216) already described in the literature as 
ALDH2-selective inhibitors.
201, 204
 Consistent with prior work, daidzin was found to be 
about 100-fold more potent toward ALDH2 than ALDH1A1 (Table 4). However our 
IC50 values are 10-fold higher than prior values, likely due to differing substrate 
concentrations in the assays. In regards to the other ALDH1/2 enzymes, we found daidzin 
to inhibit ALDH1B1 (IC50 = 5.1 ± 0.5 µM) and ALDH1A2 (IC50 = 4.5 ± 0.6 µM) with 
similar potencies to ALDH2 (IC50 = 3.5 ± 0.1 µM), while being less potent against 
ALDH1A1 and ALDH1A3. Inhibition of ALDH1A1 and ALDH1A2 by daidzin was 
observed, but compound solubility issues in the assay prevented full dose-response 
analyses. 
 
The IC50 values of the four aromatic lactones were then determined for nine ALDH 
isoenzymes (Table 4) in order to better characterize the selectivity of the compounds 
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towards individual members of the ALDH1/2 family of isoenzymes and against other 
ALDH isoenzymes. None of the four compounds inhibited the activity of ALDH1L1 
(rat), ALDH3A1, ALDH4A1, or ALDH5A1 when present in the reaction mixtures up to 
100 µM. 2BS4 showed selectivity towards ALDH2 versus the other eight isoenzymes 
tested with an IC50 value of 1.5 ± 0.3 µM. The other three compounds inhibited ALDH2 
more strongly, though they also inhibited the majority of the other ALDH1/2 isoenzymes 
at sub-micromolar concentrations. The lowest IC50 measured was that of 2P3 with ALDH 
(0.11 ± 0.02 µM), 30 times as potent as daidzin. 2P3 inhibited each of the five ALDH1/2 
isoenzymes the strongest and was the only compound which completely inhibited each of 
the five isoenzymes. 
 
Table 4 IC50 values for four aromatic lactones with nine ALDH isoenzymes. 
Values are the mean/SEM of three independent experiments, each n=3. 
  IC50 (µM) 
 Inhibitor ALDH2 ALDH1B1 ALDH1A1  ALDH1A2 ALDH1A3 
Daidzin 3.5 ± 0.1 5.1 ± 0.5 >200 4.5 ± 0.6 >200 
2CB5 0.34 ± 0.05 0.88 ± 0.28 0.34 ± 0.05
#
  0.76 ± 0.07 1.1 ± 0.1 
2P3 0.11 ± 0.02 0.36 ± 0.12 0.22 ± 0.05  0.30 ± 0.04 0.40 ± 0.06 
2P4 0.19 ± 0.01 0.31 ± 0.07
#
  NI  0.33 ± 0.04
#
 0.27 ± 0.05 
2BS4 1.5 ± 0.3 NI  NI  NI NI 
        IC50 (µM) 
 
 Inhibitor 
ALDH1L1 
(rat) 
ALDH3A1 ALDH4A1 ALDH5A1 
 Daidzin NI NI NI NI  
2CB5 NI NI NI NI 
 2P3 NI NI NI NI 
 2P4 NI NI NI NI 
 2BS4 NI NI NI NI 
 #Compounds had ~60% maximum inhibition      NI=No Inhibition 
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2P4 has a similar IC50 value for ALDH2 (0.19 ± 0.01 µM) and ALDH1A3 as 2P3, but 
only partially inhibits ALDH1B1 and ALDH1A2 and does not inhibit ALDH1A1. 2CB5 
has the highest IC50 values for the five ALDH1A/2 isoenzymes and only partially 
inhibited ALDH1A1. The number and length of alkyl substitutions on the aromatic 
lactone appears to correlate with the potency of inhibition towards the isoenzymes. This 
correlation is best seen in terms of ALDH1A1 inhibition. 2P3 and 2CB5 have a propyl 
chain proximal to the lactone carbonyl and inhibit ALDH1A1, whereas 2P4 has a methyl 
chain in the same position and does not inhibit ALDH1A1. Additionally, 2CB5 lacks the 
methyl chain proximal to the furan oxygen seen in 2P3 and does not inhibit ALDH1A1 as 
strongly as 2P3. 
 
D. Characterization of  Interaction of Aromatic Lactones with ALDH2 
1. Kinetic Characterization of 2P4 in ALDH2 Assays 
Covariation experiments were completed with 2P4 to better understand the mechanisms 
by which this compound inhibits ALDH2. 2P4 was chosen as a representative of the 
psoralen derivatives as 2P4 showed the most selectivity for inhibition of this enzyme. 
Due to the low Km of ALDH2 for propionaldehyde (<1 µM), the production of NADH by 
ALDH2 was measured via fluorescence when varying aldehyde substrate.
223
 A standard 
curve for the fluorescence of NADH was generated to convert the arbitrary fluorescence 
units to nanomoles of NADH produced (Figure 17). The Km for propionaldehyde was 49 
± 9 nM and the Km for NAD
+
 was 31 ± 4 µM using the fluorescence assay (Figure 18). 
2P4 was found to non-competitively inhibit (mixed-type) the binding of aldehyde 
substrate to ALDH2 with a Ki = 31 ± 3 nM (Figure 19A). Covariation experiments 
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varying the amount of NAD
+
 were able to be completed using the absorbance assay. 2P4 
was found to competitively inhibit the binding of NAD
+
 to ALDH2 with a Ki =87 ± 8 nM 
(Figure 19B). 
 
 
Figure 17 Standard curve for fluorescence of NADH.  
Each point represents the mean/SEM of two separate experiments of three replicates each 
(n=6). 
 
 
Figure 18 Substrate Km determination using fluorescence assay. 
The Km for (A) NAD and (B) propionaldehyde using fluorescence assay was measured. 
Each point represents the mean/SEM of one experiment consisting of three replicates 
(n=3). 
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Figure 19 Steady-state kinetic characterization of inhibition of ALDH2 by 2P4. 
(A) Lineweaver-Burk representation of (mixed-type) non-competitive inhibition of 2P4 
versus varied propionaldehyde with ALDH at fixed concentration of NAD
+
 (400 µM) 
measured via fluorescence. Values are the mean/SEM of four independent experiments, 
each n=2. (B) Lineweaver-Burk representation of competitive inhibition of 2P4 versus 
varied NAD
+
 with ALDH2 at fixed concentration of propionaldehyde (1 mM) measured 
via absorbance. Values are the mean/SEM of three independent experiments, each n=3. 
 
 
 
 
 
2. 2P3-ALDH2 Crystal Structure 
We wished to solve the structure of an enzyme-compound complex to understand where 
the aromatic lactone binds to the enzyme and what residues and interactions lead to 
selectivity. 2P3 was used for crystallographic studies as it was the most potent for 
ALDH2 among the compounds. The structure of the 2P3-ALDH2 complex was solved to 
a resolution of 2.40Å (Table 5). 
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Table 5 Collection and refinement statistics for the 2P3-ALDH2 complex. 
PDB Code 5L13 
Collection 
 
Space Group P212121 
Cell Dimensions 
 
a,b,c (Å) 99,127,295 
α,β,γ (deg) 90,90,90 
Resolution (Å) 50.0-2.40 
Rmerge 0.093 (0.280)* 
I/σ 16.2 (5.0) 
Completeness (%) 94.2 (85.7) 
Redundancy 5.0 (4.8) 
Refinement 
 
No. of reflections 131537 
Rwork/Rfree 0.16/0.21 
RMSD 
 
Bond Length (Å) 0.009 
Bond Angle (deg) 1.324 
*Values in parentheses are for data in the highest resolution shell (2.44 to 2.40 Å) 
 
 
2P3 was found to bind in the substrate binding site of ALDH2 (Figure 20A). The binding 
site is formed in part by the side chains of four phenylalanine residues (170, 296, 459, 
and 465). The side chain of the catalytic Cys302 rotates toward the NAD
+
 binding site to 
accommodate the binding of 2P3. The propyl chain proximal to the lactone extends into a 
pocket formed in part by Glu268, Glu476, Trp177, and Thr244, while the alkyl chains on 
the furan ring are oriented towards the solvent exposed surface. The carbonyl of 2P3 
mimics the position of a potential aldehyde substrate engaging the oxyanion hole during 
aldehyde oxidation and hydrogen bonds with the peptide nitrogen of Cys302 (Figure 
20B). The hydrophobic interactions and this single hydrogen bond orient the compound 
in the substrate binding site. 
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Figure 20 Crystal structure of 2P3-ALDH2 complex 
 (A) Representative electron density map of 2P3 bound to ALDH2 with the original Fo-Fc 
map in green contoured at 3.0 standard deviations and the final 2Fo-Fc map in blue 
contoured at 1.0 standard deviation. (B) Alternative viewing angle of 2P3 binding site. A 
hydrogen bond between lactone carbonyl and peptide nitrogen of Cys302 is shown as 
black dashed line. 
 
 
 
 
 
 
3. Kinetic Characterization of 2BS4 
Covariation experiments were also completed with 2BS4 for ALDH2 as 2BS4 had a 
slightly different aromatic structure, which could possibly change the inhibition profile. 
2BS4 was found to competitively inhibit the binding of NAD
+
 to ALDH2 with a Ki = 310 
± 36 nM (Figure 21). Due to the possibility that the inhibitory actions of 2BS4 are a 
result of being a competitive esterase substrate, an incubation experiment was performed. 
ALDH2 was incubated with either 3 µM or 15 µM 2BS4, or ~2x and ~10x the IC50 value, 
for up to 72 hours (Figure 22). ALDH2 incubated with 15 µM 2BS4 did not recover any 
activity upon dilution for up to 72 hours. ALDH2 incubated with 3 µM 2BS4 exhibited a 
slightly different pattern after dilution. The enzyme was not completely inhibited at first, 
which was consistent with the IC50 measurement. After one hour incubation, the 3 µM 
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2BS4/ALDH2 mixture was completely inhibited after dilution. However, the 3 µM 
2BS4/ALDH2 mixture slowly regained activity starting after one day. This would suggest 
that 2BS4 is losing the ability to inhibit ALDH2 over time, possibly through hydrolysis 
of the ester.  
 
 
 
 
Figure 21 Steady-state kinetic characterization of inhibition of ALDH2 by 2BS4. 
Lineweaver-Burk representation of competitive inhibition for 2BS4 versus varied NAD
+
 
with ALDH2 at fixed concentration of propionaldehyde (1 mM). Values are the 
mean/SEM of four independent experiments (n=4). 
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Figure 22 Incubation of ALDH2 with 2BS4. 
Dehydrogenase activity of ALDH2 after incubation with either 0 µM, 3 µM, or 15 µM 
2BS4. Each data point represents the mean of duplicate assays (n=2). 
 
 
 
 
 
The complete inhibition of ALDH2 by 2BS4 after dilution could be consistent with a 
covalent mechanism of inhibition. For this reason, IC50 curves for 2BS4 with ALDH2 
were measured using different incubation times (Figure 23). No time dependence was 
seen for the inhibition phase. 2BS4 exhibited approximately the same IC50 value after 
zero, two, or ten minutes of pre-incubation of compound and enzyme. 
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Figure 23 IC50 values for BUC22 with ALDH2 after different incubation periods. 
IC50 curves for the inhibition of ALDH2 by 2BS4 after various incubation times (0, 2, 
and 10 minutes). Values represent the mean/SEM of three individual measurements 
(n=3). 
 
 
E. Characterization of Additional Psoralen and Coumarin Analogs 
1. Single Concentration Selectivity for Structure-Activity Relationships 
Psoralen- and coumarin-derived analogs were purchased and characterized to develop 
structure activity relationships for this compound class to improve upon the selective 
selectivity of the psoralen analogs for ALDH2. Because 2BS4 selectively inhibited 
ALDH2 before subsequent hydrolysis, it was hypothesized that similar compounds 
without the ester group could reversibly inhibit ALDH2 while maintaining selectivity. A 
total of 35 compounds were ordered from ChemBridge Company (San Diego, CA) and 
ChemDiv Company (San Diego, CA) as a representative sample of available compounds 
using the binding location of 2P3 to ALDH2 as a guide. Twelve compounds share the 
psoralen sub-structure of 2P3, 2P4, and 2CB5 (Scaffold I) and twenty-three compounds 
share the coumarin sub-structure of 2BS4 (Scaffold II) (Figure 24). 
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Figure 24 Compound scaffolds of psoralen- and coumarin-derived analogs 
Depiction of scaffolds for psoralen- (Scaffold I) and coumarin-derived (Scaffold II) 
analogs with locations for potential substituents labeled R1 – R6. 
 
 
The effect of 10 µM compound on the activity of ALDH1A1, ALDH2, and ALDH3A1 
was measured as an initial estimate for selectivity amongst ALDHs (Tables 6 & 7). 
Scaffold I consists of compounds BUC1-12 in addition to 2P3, 2P4, and 2CB5. Some 
analogs had additional alkyl chains added to Scaffold 1. The addition of a t-butyl group at 
R3 (BUC1) lowered the inhibition towards ALDH2. The addition of a methyl group to R1 
(BUC2) nearly eliminated inhibition towards ALDH2. Lengthening the alkyl chain at R5 
to three carbons (BUC3) maintained inhibition towards ALDH2. Other analogs increased 
the size of the ring structure of Scaffold I. The addition of a cyclohexane to the furan ring 
(BUC4) weakened inhibition towards ALDH2. The addition of a benzyl (BUC5), 
cyclohexyl (BUC6), or cyclopentyl (BUC7) ring proximal to the lactone carbonyl 
maintained inhibition towards ALDH2 while showing some selectivity towards 
ALDH1A1 and ALDH2. The addition of a benzyl group at either R5 (BUC10) or R6 
(BUC8) led to moderate inhibition of ALDH1A1 with little to no inhibition of ALDH2. 
BUC11 and BUC12 have either a 1-(piperidin-1-yl)propan-1-one (BUC11) or N-
benzylpropionamide (BUC12) group at R6. The 1-(piperidin-1-yl)propan-1-one linker is 
tolerated as BUC11 inhibits both ALDH1A1 and ALDH2 >90% at 10 µM. BUC12 was 
the only compound within Scaffold I which showed inhibition towards ALDH3A1. 
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Table 6 Structure activity relationships for psoralen derivatives. 
Percent activity compared to control was measured at 10 µM compound with ALDH1A1, 
ALDH2, and ALDH3A1. Compounds picked for further study highlighted in gray. Mean 
value from at least three trials (n≥3). 
 
Cmpd 
Scaffold I Position 
LogP 
% Activity 
R1 R2 R3 R4 R5 R6 
ALDH
1A1 
ALDH
2 
ALDH
3A1 
2CB5 H H Me H Me propyl 4.47 48.6 6.25 96.1 
2P3 H Me Me H Me propyl 4.92 36.3 1.61 86.3 
2P4 H Me Me H Me Me 4.39 90.5 19.5 95.3 
BUC1 H H t-Bu H Me Me 3.94 94.5 69.7 87.0 
BUC2 Me Me Me H Me Me 4.36 78.4 87.2 102 
BUC3 H Me Me H propyl H 4.47 74.1 23.8 80.4 
BUC4 H 
  
H Me Me 4.48 64.3 61.3 96.1 
BUC5 H Me Me H 
  
3.89 82.4 42.2 93.4 
BUC6 H Me Me H 
  
4.27 56.3 16.3 94.1 
BUC7 H Me Me H 
  
4.26 50.8 8.25 87.1 
BUC8 H H Me H Me benzyl 4.98 58.5 83.6 90.3 
BUC9 H H phenyl H Me Me 4.80 87.4 92.8 88.9 
BUC10 H Me Me H benzyl H 4.80 57.0 73.7 81.6 
BUC11 H Me Me H Me 
  
4.06 8.69 3.80 105 
BUC12 H Me Me H Me 
 
4.52 93.6 69.8 68.3 
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Table 7 Structure activity relationships for coumarin derivatives. 
Percent activity compared to control was measured at 10 µM compound with ALDH1A1, 
ALDH2, and ALDH3A1. Compounds picked for further study highlighted in gray. Mean 
value from at least three trials (n≥3). 
 
Cmpd 
Scaffold II Position 
LogP 
% Activity 
R1 R2 R3 R4 R5 R6 
ALDH
1A1 
ALDH
2 
ALDH
3A1 
BUC13 H Me 
  
Me Me 3.92 71.5 46.4 98.1 
BUC14 
 
H H H H 1.77 61.0 95.2 28.3 
BUC15 Me 
  
H Me Me 2.10 67.4 80.2 79.2 
BUC16 H 
 
H Me H 2.11 65.2 25.5 53.6 
BUC17 H 
 
H H Me H 3.01 35.5 94.6 9.46 
BUC18 H 
 
H H Me H 3.94 37.3 93.3 23.7 
BUC19 H 
 
H H Me H 3.19 29.0 97.8 67.1 
BUC20 H 
 
H H Me H 1.22 35.7 41.3 20.4 
BUC21 H 
 
H H Me H 2.85 49.6 95.0 95.5 
BUC22 H 
 
H H Me H 3.63 14.3 71.7 109 
BUC23 H 
 
H H Me H 3.92 8.80 101 41.5 
BUC24 H 
  
H H 
 
2.64 58.7 64.4 103 
BUC25 H 
  
H H Me benzyl 3.44 24.6 99.7 86.9 
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Table 7, continued Structure activity relationships for coumarin derivatives. 
Percent activity compared to control was measured at 10 µM compound with ALDH1A1, 
ALDH2, and ALDH3A1. Compounds picked for further study highlighted in gray. Mean 
value from at least three trials (n≥3). 
 
Cmpd 
Scafford II Position 
LogP 
% Activity  
R1 R2 R3 R4 R5 R6 
ALDH
1A1 
ALDH
2 
ALDH
3A1 
BUC26 H OH H H Me 
 
 
1.82 96.6 101 105 
BUC27 H H Br H H 
 
 
2.10 96.0 48.2 91.7 
BUC28 H Me 
 
H Me H 2.05 59.8 96.3 105 
2BS4 H 
 
H H Me H 1.90 84.8 5.72 94.5 
2BS4A H 
  
H H Me H 1.90 68.7 94.4 101 
2BS4B H 
 
H H Me H 1.72 52.2 99.1 64.1 
2BS4C H 
  
H H Me H 1.37 91.4 93.3 106 
2BS4D H 
 
 
H H Me H 1.71 28.5 89.5 67.1 
2P14 H 
  
H H Me H 2.46 80.2 94.8 36.4 
2P15 H 
  
H H Me H 1.63 97.5 99.3 93.9 
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Scaffold II compounds are variations of 2BS4, but all lack the ester group of 2BS4. Three 
different methyl ketones (2BS4A-C) similar to 2BS4 did not inhibit ALDH2. 2BS4A and 
2BS4B also inhibited ALDH1A1 and/or ALDH3A1 while 2BS4C did not inhibit any of 
the three isoenzymes. An amide (2BS4D) similar to 2BS4 only inhibited ALDH1A1 
activity. Shorting the side chain of 2BS4 to the methyl ether (2P14) led to inhibition of 
ALDH3A1; while the free acid form of 2BS4 (2P15) did not inhibit any of the three 
isoenzymes.  
 
More diverse additions to Scaffold II were also examined (BUC13-28). The addition of 
oxygen-containing rings had varied results. A 3-methylfuran ring at R3 and R4 (BUC13) 
led to partial inhibition of ALDH2 while addition of a furan ring at R1 and R2 (BUC14) 
led to strong inhibition of ALDH3A1 with no inhibition of ALDH2. The addition of 4H-
pyran-4-one at R2 and R3 (BUC15) led to slight inhibition of ALDH1A1. The addition of 
δ-valerolactone at R2 and R3 (BUC16) led to inhibition of ALDH2 with lesser inhibition 
of ALDH1A1 and ALDH3A1. Compounds BUC17-BUC23 changed the methyl 2-
methoxypropanoate group at R2 in 2BS4 to more diverse structural groups. BUC17 and 
BUC18 contain unsaturated alkyl chains at R2 and inhibit ALDH1A1 and ALDH3A1. 
BUC19 has a 2-oxo-2-phenylethoxy group and inhibits ALDH1A1 with moderate 
inhibition of ALDH3A1. BUC20 has a terminal nitrile and inhibits ALDH1A1, ALDH2, 
and ALDH3A1 at similar levels. BUC21 and BUC22 both appear to selectively inhibit 
ALDH1A1, though BUC21 only inhibits 50% at 10 µM mostly due to the large N-
phenylacetamdie group at R2. BUC22 contains a diethylamine in the same position and 
inhibits ALDH1A1 ~85% at 10 µM. BUC23, which substituted a 1,4-
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bis(methoxymethyl)benzene at R2, strongly inhibited ALDH1A1 with partial inhibition 
towards ALDH3A1. Compounds BUC24-28 have changes at multiple positions 
compared to 2BS4. BUC24 has a (3-oxobutan-2-yl)oxy group at R2 and benzyl ring 
attached at R5 and R6 which led to moderate inhibition of ALDH1A1 and ALDH2. 
BUC26 has a hydroxyl group at R2 and propionic acid group at R6 and did not inhibit any 
of the three isoenzymes. The other three compounds showed some level of selectivity for 
either ALDH1A1 or ALDH2. BUC25, which added a methane sulfonyl group at R2 and a 
benzyl group at R6, and BUC28, which added isobutyramide at R3, selectively inhibited 
ALDH1A1 and BUC27, which has only hydrogen at R2 and added a bromine at R3 and 
ketoxime at R6, selectively inhibited ALDH2. Of the 35 additional analogs tested, seven 
showed potential selectivity for ALDH2 based off activity at 10 µM compound (BUC3, 
BUC5-BUC7, BUC13, BUC16, and BUC27). Three compounds showed potential 
selectivity towards ALDH1A1 (BUC22, BUC23, and BUC25). These ten compounds and 
BUC11, which inhibited both ALDH1A1 and ALDH2 >90% at 10 µM compound, were 
selected for further analysis. 
 
Due to the hydrophobic nature of the substrate binding site within the free enzyme 
species of ALDH2, the logP values for the 35 analogs in addition to the initial four hits 
were examined (Table 4). No direct correlation between logP values and inhibition of 
ALDH2 could be developed. For example, BUC3 and BUC16 both inhibit ALDH2 with 
the same potency at 10 µM compound and have vastly different logP values. Although 
BUC3 has a logP value of 4.47 and BUC16 has a logP value of 2.11, both compounds 
inhibit ALDH2 ~75% at 10 µM compound. 
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2. EC50 Determination 
EC50 values were measured in regards to ALDH1A1, ALDH2, and ALDH3A1 for the 
eleven selected compounds as a better measure of selectivity and potency. Four 
compounds did not show selectivity or full inhibition for ALDH1A1 or ALDH2 (Table 
8). We sought complete inhibitors of the isoenzymes, so BUC5 and BUC13 were not 
examined further as they only partially inhibited ALDH2. BUC16 and BUC23 had sub-
micromolar IC50’s for ALDH2 and ALDH1A1 respectively; however, both partially 
inhibited ALDH3A1. As these compounds were no longer selective for the ALDH1/2 
family, these compounds were also not examined further. 
 
 
Table 8 IC50 values for four analogs with ALDH1A1, ALDH2, and ALDH3A1.  
Values are the mean/SEM of three independent experiments (n=3). 
Compound Structure 
IC50 (µM) 
ALDH1A1 ALDH2 ALDH3A1 
BUC5 
 
NI 0.15 ± 0.01
#
 NI 
BUC13 
 
NI 0.15 ± 0.01
#
 NI 
BUC16 
 
NI 0.47 ± 0.02 5.4 ± 1.0
#
 
BUC23 
 
0.17 ± 
0.01 
NI 
0.50 ± 
0.05
#
 
#
50-60% max inhibition      NI= No inhibition 
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The other seven compounds did not inhibit ALDH3A1 and fully inhibited ALDH1A1 
and/or ALDH2. EC50 values for ALDH1B1, ALDH1A2, and ALDH1A3 were also 
measured in addition to those for ALDH1A1, ALDH2, and ALDH3A1 for these seven 
compounds (Table 9). Compounds BUC3, BUC6, and BUC7 inhibit the majority of the 
ALDH1/2 family with sub-micromolar IC50 values but exhibit little selectivity within the 
family. Each one of the three compounds fully inhibits ALDH2, ALDH1B1, and 
ALDH1A2 and does not inhibit ALDH3A1. The three compounds have differing effects 
towards ALDH1A1 and ALDH1A3. BUC3 does not inhibit ALDH1A1 and activates 
ALDH1A3 ~2-fold with an AC50 value of 0.87 ± 0.09 µM. BUC6 partially inhibits 
ALDH1A1 and does not inhibit ALDH1A3. BUC7 partially inhibits both ALDH1A1 and 
ALDH1A3. BUC11 also does not show selectivity within the ALDH1/2 family, though it 
does show ~10-fold preference towards inhibiting ALDH1A1 (IC50 = 0.13 ± 0.01 µM) 
versus the other four ALDH1/2 isoenzymes. BUC22 was found to selectively inhibit 
ALDH1A1 (IC50 = 0.76 ± 0.07 µM) with only minor effects on ALDH1A2. BUC25 
showed a preference towards ALDH1A1 (IC50 = 2.8 ± 0.1 µM) while not inhibiting 
ALDH2. BUC27 selectively inhibited ALDH2 (IC50 = 4.6 ± 0.5 µM) while also 
exhibiting two-fold activation of ALDH1A3 (AC50 = 35 ± 3 µM). 
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Table 9 EC50 values for seven analogs with the ALDH1/2 family and ALDH3A1.  
The coumarin derivatives are more potent, while the psoralen derivatives are more 
selective. AC50 curves had a maximum activity of ~200% control. Values are the 
mean/SEM of three independent experiments (n=3). 
 
Compound Structure 
IC50 (µM) 
ALDH
2 
ALDH
1B1 
ALDH
1A1 
ALDH
1A2 
ALDH
1A3 
ALDH
3A1 
BUC3 
  
0.36 ± 
0.03 
0.086 
± 
0.002 
NI 
0.069 
± 
0.009 
 AC50     
0.87 ± 
0.09 
NI 
BUC6 
  
0.067 
± 
0.006 
0.095 
± 
0.015 
0.13 ± 
0.01
#
 
0.065 
± 
0.004 
NI NI 
BUC7 
  
0.067 
± 
0.003 
0.16 ± 
0.01 
0.17 ± 
0.02
#
 
0.13 ± 
0.01 
0.17 ± 
0.02
#
 
NI 
BUC11 
  
2.0 ± 
0.2 
2.6 ± 
0.3 
0.13 ± 
0.01 
1.6 ± 
0.1 
14 ± 1 NI 
BUC22 
  
NI NI 
0.76 ± 
0.07 
>10 NI NI 
BUC25 
  
NI 13 ± 1 
2.8 ± 
0.1 
11 ± 1 10 ± 1 NI 
BUC27 
  
4.6 ± 
0.6 
NI NI NI 
 AC50        
35 ± 3 
NI 
#
50-60% max inhibition   NI= No Inhibition 
 
 
3. Characterization of BUC11’s Interaction with ALDH1A1 and ALDH2 
The interaction of BUC11 with ALDH1A1 and ALDH2 was investigated further through 
the use of X-ray crystallography and kinetic studies. The structure of BUC11 bound to 
ALDH1A1 in the absence of coenzyme was solved to a resolution of 1.70Å (Table 10).  
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Table 10 Collection and refinement statistics for the BUC11-ALDH1A1 complex. 
PDB Code 5L2M 
Collection  
Space Group P422 
Cell Dimensions  
a,b,c (Å) 109,109,83 
α,β,γ (deg) 90,90,90 
Resolution (Å) 50.0-1.70 
Rmerge 0.119 (0.526)* 
I/σ 17.2 (5.5) 
Completeness 
(%) 
98.4 (97.6) 
Redundancy 12.6 (12.2) 
Refinement  
No. of reflections 52110 
Rwork/Rfree 0.23/0.26 
RMSD  
Bond Length (Å) 0.011 
Bond Angle 
(deg) 
1.500 
* Values in parentheses are for data in the highest resolution shell (1.73 to 1.70Å) 
 
 
BUC11 was found to bind within the substrate binding site of ALDH1A1 (Figure 25A) 
with the psoralen backbone oriented between Tyr297, Gly458, His293, and Phe290. The 
piperidine ring of BUC11is oriented towards the catalytic cysteine rather the carbonyl of 
the lactone as seen with 2P3 bound to ALDH2. The piperidine ring in this position does 
not approach the NAD(H) binding site (Figure 25B). Covariation experiments were used 
to evaluate if the change in binding site changed the enzymatic mechanism of inhibition. 
BUC11 was found to exhibit uncompetitive inhibition (Ki = 170 ± 13 nM) versus varied 
NAD
+
 for ALDH1A1 (Figure 26A). However, BUC11 was found to exhibit competitive 
inhibition (Ki = 1.1 ± 0.1 µM) versus varied NAD
+
 for ALDH2 (Figure 26B). 
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Figure 25 Crystal structure of BUC11-ALDH1A1 complex. 
(A) Electron density map of BUC11 bound to ALDH2 with the original Fo-Fc map in 
green contoured at 2.5 standard deviations and the final 2Fo-Fc map in blue contoured at 
1.0 standard deviation. (B) Comparison of binding modes of BUC11 (black) bound to 
ALDH1A1 (orange) and 2P3 (yellow), NADH (green), and NAD
+
 (purple) bound to 
ALDH2. NAD
+
/NADH binding positions obtained from PDB1O02 and 1O04. 
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Figure 26 Steady state kinetic characterization of BUC11 with ALDH enzymes. 
(A) Lineweaver-Burk representation of uncompetitive inhibition for BUC11 versus 
varied NAD
+
 with ALDH1A1 at fixed concentration of propionaldehyde (1 mM). (B) 
Lineweaver-Burk representation of competitive inhibition for BUC11 versus varied 
NAD
+
 with ALDH2 at fixed concentration of propionaldehyde (1 mm). Vales are 
mean/SEM of three independent experiments (n=3). 
 
 
 
 
 
 
4. Characterization of BUC25’s Interaction with ALDH1A1 
The interaction of BUC25 with ALDH1A1 was investigated further by solving the crystal 
structure of BUC25 bound to ALDH1A1 to a resolution of 1.70 Å (Table 10).  BUC25 
binds in the substrate binding site (Figure 27A) and the lactone carbonyl is oriented 
towards the catalytic cysteine though not as close as 2P3 bound to ALDH2 (Figure 27B). 
The additional benzyl group would appear to prevent the compound from approaching 
the catalytic cysteine. Although the electron density for the benzyl group of BUC25 was 
not as strong as the remainder of the compound, its position and movement of Trp178 
was reminiscent of the interaction between CM037 and ALDH1A1 in the same region 
which has similar weak density near Trp178.
216
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Table 11 Collection and refinement statistics for the BUC25-ALDH1A1 complex. 
PDB Code 5L2N 
Collection 
 
Space Group P422 
Cell Dimensions 
 
a,b,c (Å) 109,109,83 
α,β,γ (deg) 90,90,90 
Resolution (Å) 50.0-1.70 
Rmerge 0.094 (0.639)* 
I/σ 16.9 (3.3) 
Completeness 
(%) 
100 (100) 
Redundancy 8.4 (8.2) 
Refinement 
 
No. of reflections 52587 
Rwork/Rfree 0.23/0.26 
RMSD 
 
Bond Length (Å) 0.012 
Bond Angle 
(deg) 
1.538 
*Values in parentheses are for data in the highest resolution shell (1.73 to 1.70Å) 
 
 
 
 
 
Figure 27 Crystal structure of BUC25-ALDH1A1 complex. 
(A) Electron density map of BUC25 bound to ALDH1A1 with the original F0-Fc map in 
green contoured at 2.5 standard deviations and the final 2Fo-Fc map in blue contoured at 
1.0 standard deviation. (B) Overlay of BUC25 (black) bound to ALDH1A1 (orange) and 
2P3 (yellow) bound to ALDH2 (cyan). 
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5. Characterization of BUC22’s Interaction with ALDH1A1 
The interaction of BUC22 with ALDH1A1 was examined by X-ray crystallographic and 
enzyme kinetic studies. The structure of the BUC22-ALDH1A1 complex was solved to a 
resolution of 2.05Å in the P1 space group (Table 12).  
 
Table 12 Collection and refinement statistics for the BUC22-ALDH1A1 complex. 
PDB Code 5L2O 
Collection 
 
Space Group P1 
Cell Dimensions 
 
a,b,c (Å) 91,98,127 
α,β,γ (deg) 81,86,64 
Resolution (Å) 50.0-2.05 
Rmerge 0.069 (0.280)* 
I/σ 10.7 (2.7) 
Completeness (%) 90.8 (91.7) 
Redundancy 2.1 (2.1) 
Refinement 
 
No. of reflections 211433 
Rwork/Rfree 0.17/0.20 
RMSD 
 
Bond Length (Å) 0.011 
Bond Angle (deg) 1.397 
*Values in parentheses are for data in the highest resolution shell (2.09 to 2.05Å) 
 
 
This space group was different than those of the BUC11-ALDH1A1 and BUC25-
ALDH1A1 complexes and consisted of two tetramers in the asymmetric unit as opposed 
to a single monomer. BUC22 binds in the coenzyme binding site of ALDH1A1 (Figure 
28A) near Pro227 and Val250 similar to the adenine of NAD
+
. The aromatic ring 
structure of BUC22 is rotated slightly from that of adenine in this position (Figure 28B). 
The binding site of BUC22 is removed from that of 2P3 in ALDH2 and BUC11 and 
BUC25 in ALDH1A1. Covariation experiments were completed to further characterize 
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BUC22’s interaction with ALDH1A1. BUC22 was found to exhibit non-competitive 
inhibition versus varied NAD
+
 for ALDH1A1 (Figure 29A) with Ki = 1.2 ± 0.1 µM. This 
mode of inhibition is different from that of 2P3 in ALDH2 and BUC11 and BUC25 in 
ALDH1A1. A compound similar to BUC22 was used to further support the kinetic data 
of BUC22. BUC20 replaces the diethylamine of BUC22 with a terminal cyano group and 
inhibits both ALDH1A1 and ALDH2. BUC20 was found to exhibit noncompetitive 
inhibition versus varied NAD
+
 for ALDH1A1 (Figure 29B) and noncompetitive (mixed-
type) inhibition versus varied NAD
+
 for ALDH2 (Figure 29C). 
 
Figure 28 Crystal structure of BUC22-ALDH1A1 complex. 
(A) Representative electron density map of BUC22 bound to ALDH1A1 with the original 
Fo-Fc map in green contoured at 2.5 standard deviations and the original 2Fo-Fc map in 
blue contoured at 1.0 standard deviation. (B) Overlay of BUC22 and NADH (PDB 
4WB9) bound to ALDH1A1.  
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Figure 29 Steady-state kinetic characterization of inhibition by BUC22 and BUC20. 
(A) Lineweaver-Burk representation of noncompetitive inhibition for BUC22 versus 
varied NAD
+
 with ALDH1A1. (B) Lineweaver- Burk representation of noncompetitive 
inhibition for BUC20 versus varied NAD
+
 with ALDH1A1. (C)Lineweaver-Burk 
representation of noncompetitive inhibition (mixed-type) inhibition for BUC20 with 
varied NAD
+
 with ALDH2. All experiments completed at fixed concentration of 
propionaldehyde (1 mM). Values are the mean/SEM of three independent experiments 
(n=3). 
 
 
6. Characterization of BUC27’s Interaction with ALDH2 
BUC27 was the lone ALDH2-selective compound that was not an ester discovered in this 
study. Covariation experiments were performed to determine how BUC27 inhibits 
ALDH2. BUC27 was found to competitively inhibit the binding of NAD
+
 to ALDH2 
with a Ki = 2.4 ± 0.1 µM (Figure 30). 
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Figure 30 Steady-state kinetic characterization of inhibition of ALDH2 by BUC27. 
Lineweaver-Burk representation of competitive inhibition for BUC27 versus varied 
NAD
+
 with ALDH2 at fixed concentration of propionaldehyde (1 mM). Values are the 
mean/SEM of three independent experiments (n=3). 
 
F. Effect of BUC22 on Viability of Breast Cancer Cells in 3D Culture 
The cellular effects of BUC22 were examined by treating MDA-MB-468 cells over the 
course of five days. Results were compared to the effect of 30 µM CM39, which had 
previously been shown to inhibit the proliferation of MDA-MB-468 cells by Brandon 
Lane (IUSM) and has been used in collaborative studies with the University of Michigan 
in A2780DK ovarian cancer cells to achieve similar results. High concentrations of 
BUC22 decreased cell proliferation as measured by the MTT assay. Treatment of 100 
µM BUC22 over a period of five days led to a ~2-fold decrease in mitochondrial function 
(Figure 31). This was close to the same effect that 30 µM CM39 had on the same cell 
line.  
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Figure 31 Effect of BUC22 treatment on proliferation of breast cancer cells 
MTT assay was performed on MDA-MB-468 cells after treatment with BUC22 for five 
days. CM39 was included as a positive control for inhibition. Values are the mean/SEM 
of three independent experiments relative to vehicle control, each n=3. *p<0.01 versus 
vehicle 
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IV. Discussion 
The ALDH1/2 family plays a major role in many physiological processes and 
pathologies. Five members of the family share approximately 70% protein sequence 
identity and demonstrate significant overlap in their substrate specificity. Consequently, 
selective inhibitors of these enzymes would help better delineate their individual 
function. Although the cofactor binding site is highly conserved amongst ALDH 
isoenzymes, there are distinct differences within the substrate binding sites that support 
the discovery of compounds which could selectively target individual isoenzymes.  For 
example, the substrate binding site of ALDH2 is the narrowest and most hydrophobic. 
Although inhibition of ALDH2 has been utilized as an approach for the treatment of 
alcohol abuse for over 60 years, selective inhibitors of ALDH2 remain elusive.
219
  Based 
on prior success in finding selective modulators for ALDH1A1 and ALDH3A1 by high-
throughput screening, we performed a high-throughput screen to identify potential 
inhibitors and activators of ALDH2.
214, 220
 
 
Our high-throughput screen encompassed over 110,000 compounds. The primary screens 
identified 1931 compounds that met our selection criteria; of these, 67 compounds (<5%) 
rose to the same selection criteria during retest of the hits. HTS are inherently noisy and 
produce many false positives. For example, outliers were found in the Z’-factor 
determination (Figures 10 & 11) from identical reactions run simultaneously on the same 
plate. False positives can occur due to spectral interference from compounds, robot 
pipetting errors, debris or bubbles in the well, misalignment of the plate during plate 
reading, or inaccuracies in compound concentration. For instance, during Screen 2 the 
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robot failed to pipet substrate to a subset of wells on several plates; these compounds 
were included in the secondary screen for evaluation to ensure complete library coverage. 
The secondary screen was designed to remove false positives from further consideration, 
saving time and resources.  
 
The effect of 59 of the 67 compounds identified via the esterase HTS on the 
dehydrogenase activity of ALDH1A1, ALDH2, and ALDH3A1 was examined as an 
initial determination of selectivity. Only 9 of the 59 compounds modulated the 
dehydrogenase activity of ALDH2 by more than 20% at 10 µM concentration, the same 
concentration tested in the HTS. Switching to the dehydrogenase assay eliminates more 
false positives as the assay is not dependent on the same readout. Additionally, 
compound concentration in the HTS is determined by the average mass of the compounds 
in the entire library. After purchase of compounds, the concentrations tested in the 
dehydrogenase assay are most likely not identical. This may eliminate compounds which 
were near the selection threshold, but whose concentration was underestimated with the 
assumptions made in the HTS. 
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Figure 32 Effect of different compounds on esterase and dehydrogenase assays. 
In the absence of NAD
+
 (a), only ester hydrolysis will occur. NAD
+
 (b) or compounds 
1(c) or 2 (d), which block one end of the tunnel, will activate esterase activity. Compound 
1 will not inhibit dehydrogenase activity unless it can outcompete NAD
+
. Compound 2 
could also activate oxidation provided the substrate can fit between the compound and 
the catalytic cysteine. Compound 3 (e), which blocks access to the catalytic cysteine, 
would inhibit both reactions. Compound 4 (f) would prevent NAD
+
 binding and inhibit 
aldehyde oxidation, but would have minimal effects on esterase activity. 
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The esterase screen may also identify compounds which activate the esterase reaction in a 
similar fashion to NAD
+
 by binding in the coenzyme binding site closing one end of the 
catalytic tunnel resulting in more productive encounters between the ester substrate and 
the catalytic cysteine (Figure 32-c).
55
 These compounds may not be able to bind to the 
enzyme in the presence of NAD
+
, minimizing their effect on dehydrogenase activity. 
Other compounds which bind in the coenzyme binding site but do not alter access to the 
tunnel would not be identified through the HTS (Figure 32-f). This limits the 
identification of compounds that bind in the NAD
+
-binding site, as many of these 
compounds would not be selective due to the high conservation of the site among ALDH 
enzymes.  
 
Although initial characterization of the compounds interaction with ALDH2 did not 
identify any substantial activators of ALDH dehydrogenase activity, three compounds 
(2CD11, 2CB8, and 2CB9) shared the benzodioxol of Alda-1, the ALDH2 activator, and 
were examined further. Alda-1 binds to ALDH2 similar to compound 2 in Figure 32-d 
with the benzodioxol group in the substrate binding site oriented towards the catalytic 
cysteine. Alda-1 displays substrate-dependent effects due to the limited space between 
the compound and the catalytic cysteine in the substrate binding site. Like Alda-1, the 
three compounds also exhibit substrate-dependent activation of ALDH2. The three 
compounds most likely bind in a similar position in ALDH2 as the activator Alda-1, 
where smaller substrates can still access the active cysteine. However, the three 
compounds are less potent activators than Alda-1.
55
 These compounds and Alda-1 have 
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similar solubility issues, and the additional decreased potency of the compounds made it 
difficult to complete full dose-response curves. 
 
The HTS identified a class of four aromatic lactones which selectively inhibit the 
ALDH1/2 family. The four compounds can be further divided by kinetic data and 
structure similarity into three psoralen derivatives and one coumarin derivative. The three 
psoralen derivatives inhibit most or all of the ALDH1/2 family with IC50 values between 
0.1 – 1.0 µM. The differences in alkyl substituents to the psoralen substructure have a 
measurable impact on the inhibition of the ALDH1/2 family. The additional methyl 
groups at positions R2 and R3 on the furan ring increase inhibition towards the ALDH1/2 
family, most likely due to increased hydrophobic contacts (Figure 33).   
 
 
Figure 33 Orientation of 2P3 in catalytic tunnel of ALDH2. 
2P3 is shown in its binding location in the catalytic site of ALDH2. Substituent positions 
are labeled. 
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Figure 34 Comparison of NAD
+
 and 2P3 binding to ALDH2. 
(A) Overlay of 2P3 (black) bound to ALDH2 (orange) and NAD
+
/NADH (purple/green) 
bound to ALDH2 (cyan). (B) Zoomed-in view of same overlay showing surface of 
ALDH2 for each binding partner. (PDB 1O00, 1O02, 1O04) 
 
 
2P4 was found to be competitive with respect to varied NAD
+
 and non-competitive 
(mixed-type) with respect to varied propionaldehyde; however, the closely related analog 
2P3 was found to bind in the substrate binding site. Binding in the substrate binding site 
would normally be expected to exhibit competitive inhibition with respect to varied 
aldehyde. The binding of 2P3 causes Cys302 to rotate toward the NAD
+
 binding site 
(Figure 34). When Cys302 resides in this shifted position, NAD
+
 cannot be productively 
positioned to accept the hydride ion during the dehydrogenase reaction. The propyl chain 
at position R6 of 2P3 may also hinder the positioning of the nicotinamide ring of NAD
+
. 
Similarly, 2P3 cannot bind to the free enzyme form of ALDH2 if Cys302 is not rotated 
away. Consequently, the binding of 2P3 prevents the productive binding of NAD
+
 and 
vice versa. Although the majority of 2P3 binds within the substrate binding site, just 
enough of the compound overlaps with the NAD
+
 binding site to generate the competitive 
inhibition towards varied NAD
+
 seen with 2P4. NAD
+
 will bind to the enzyme first and 
94 
can adopt multiple conformations (Figure 5) prior to assuming the productive 
conformation required for catalysis.
43, 48
 2P3 could bind to one of the non-productively 
positioned complexes with NAD
+
. These off-pathway complexes would be consistent 
with the non-competitive (mixed-type) inhibition towards aldehyde substrate. Although 
NAD
+
 and 2P3/4 could be bound to ALDH2 simultaneously, 2P3/4 must dissociate 
before NAD
+
 can isomerize into a productive conformation for hydride transfer (Figure 
35). Once NAD
+
 is in the correct position, substrate aldehyde will bind to the enzyme and 
the reaction proceeds. ALDH2 most likely follows an ordered bi-bi mechanism where 
NADH is released last.
43, 48
 2P3 cannot bind to the enzyme alongside NADH (Figure 34), 
so NADH must be released before 2P3/4 can bind to the enzyme again to inhibit the 
reaction. 
 
 
95 
 
Figure 35 Schematic of 2P3/4 inhibition of ALDH2 
2P4 exhibits competitive inhibition with respect to varied NAD
+
 and non-competitive 
(mixed-type) with respect to varied propionaldehyde. 2P3 can bind to the free enzyme, 
and it is possible and likely that 2P3 can also bind simultaneously with NAD
+
 in a non-
productive conformation. Isomerization of NAD
+
, and subsequent aldehyde oxidation, 
can only occur once 2P3/4 dissociates from the enzyme. 
 
 
Of the four initially identified lactones, 2BS4 has the most unique inhibition profile. 
2BS4 is less potent than 2P3/4 but is selective for ALDH2 against all other tested ALDH 
isoenzymes. Although 2BS4 contains the aromatic lactone moiety which helps orient 2P3 
in the substrate binding site, 2BS4 also contains a terminal ester group and could be a 
potential substrate for ALDH2. Either the lactone carbonyl or the terminal ester could be 
oriented towards the catalytic cysteine of ALDH2 based off the binding position of 2P3. 
Data shows that the ester of 2BS4 is slowly hydrolyzed over time, possibly through a 
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combination of ALDH2-catalyzed and non-catalyzed hydrolysis in solution. The relative 
contribution of each is unclear due to the timeframe (2-3 days). 2BS4 exhibits a time-
dependence for inhibition, but the time-dependence was not observed for the inhibition 
phase, but is related to how long the enzyme remains inhibited after complex formation. 
2BS4 behaves like a “slow off” inhibitor of ALDH2. The hydrolysis limits the use of 
2BS4 as an ALDH2 inhibitor for in vivo studies, since the free acid form is not inhibitory 
(see below). 
 
A total of 35 aromatic lactone analogs were purchased in an attempt to improve the 
selectivity of the three psoralen compounds for ALDH2, and to achieve the selectivity 
seen with the coumarin 2BS4, minus the ester group. Although the analogs were picked 
based off the binding position of 2P3 to ALDH2, many of the analogs do not inhibit 
ALDH2 activity. The narrow catalytic tunnel of ALDH2 limits the size of substituents 
that can be added to the structure of the scaffold (Figure 33). Several compounds were 
also ordered to confirm the binding mode of 2P3 since additions at certain positions to 
the compound should eliminate ALDH2 inhibition. For instance, BUC2 has a methyl 
group at position R1 which no longer fits within the narrow binding tunnel and does not 
inhibit ALDH2. There are many other compounds that have larger additions at position 
R1 that were not ordered; these compounds would also not inhibit ALDH2. Bulky side 
chains such as t-butyl and phenyl groups at position R3 or benzyl groups at positions R5 
or R6 also cause the compound to no longer fit as well in the narrow tunnel. The best 
additions amongst the psoralen compounds (Scaffold I) were increasing the size of the 
alkyl substitutions at positions R5 and R6 adjacent to the lactone carbonyl carbons, 
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including the addition of a fourth ring. The coumarin analogs which most closely 
resembled 2BS4 did not inhibit ALDH2, supporting the idea that 2BS4 inhibits the 
enzyme differently than the other compounds in the series. Carboxylates are generally 
poor inhibitors of the ALDH1/2 family, as in the case for the free acid of 2BS4 (2P15) 
and the inhibition of 2BS4 appears to be derived from the terminal ester. Several of the 
coumarin analogs inhibit the activity of ALDH3A1, suggesting the additional furan ring 
of the psoralen compounds helps select against ALDH3A1, though is not essential.  After 
initial testing with ALDH1A1, ALDH2, and ALDH3A1, 11 of the additional analogs 
warranted further dose-response analysis. 
 
The eleven compounds showed the same similar pattern at the four initial aromatic 
lactones; that is, the psoralen derivatives are more potent, but less selective, than the 
coumarin derivatives. BUC5, BUC6, and BUC7 add an additional ring structure at 
positions R5 and R6 proximal to the aromatic lactone (Figure 33). The additional 
cyclohexyl and cyclopentyl rings in BUC6 and BUC7 slightly increase the potency 
towards ALDH2 while lessening the total amount of inhibition towards ALDH1A1 and 
ALDH1A3. BUC3, which opens the cyclopentyl ring of BUC7 to form a propyl chain at 
position R5, also does not inhibit ALDH1A1, though BUC3 does activate ALDH1A3 
through a-yet-unknown mechanism. BUC5, which increases the size of the aromatic ring 
structure by adding a benzyl ring, only partially inhibits ALDH2 while selecting against 
ALDH1A1 inhibition. The amount of inhibition towards ALDH1A1 and ALDH2 by 
these compounds with larger rings is most likely related to how well the larger compound 
fits in the active site. The ring additions at R5 and R6 must fit between Trp177 and 
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Met174 in ALDH2, which are both conserved throughout the ALDH1/2 family (Figure 
33). The benzyl ring of BUC5 may not fit as well due to the constraints of maintaining 
aromaticity whereas the cyclopentyl and cyclohexyl rings do not have these restraints.  
 
BUC11 represents a large number of available analogs which use a 1-acylpiperidine 
linker to connect the psoralen ring structure to a variety of other chemical moieties. These 
compounds also have variations in the amount of alkyl substituents on the psoralen 
scaffold, similar to 2P3, 2P4, and 2CB5. BUC11 exhibits different modes of inhibition 
towards varied NAD
+
 for ALDH1A1 and ALDH2, suggesting that BUC11 inhibits these 
two enzymes through different mechanisms. BUC11 exhibits uncompetitive inhibition 
towards varied NAD
+
 for ALDH1A1, which is consistent with the distance between the 
NAD
+
 and BUC11 binding sites in ALDH1A1 (Figure 25B) and is expected for 
compounds that displace aldehyde substrates for ordered Bi Bi systems. The competitive 
inhibition towards varied NAD
+
 for ALDH2 is similar to the mechanism exhibited by 
2P4. This would suggest that BUC11 binds to ALDH2 in a similar position as 2P3 with 
the 1-acylpiperidine extending past Cys302 and posed toward the NAD
+
 site, consistent 
with its competitive mode of inhibition. However, for ALDH1A1 the presence of Gly458 
and its larger substrate pocket promotes a shift in binding mode and mechanism of 
inhibition for BUC11. The corresponding residue to Gly458 in the other four ALDH1/2 
isoenzymes is either an asparagine or aspartate, which precludes the binding mode 
observed in ALDH1A1. The 1-acylpiperide may have more difficulty extending into the 
NAD
+
 site for ALDH1A3, as the IC50 value is 10x larger than those for ALDH2, 
ALDH1B1, and ALDH1A2. 
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The coumarin derivative BUC25 also binds in the substrate binding site. The distance 
between the carbonyl lactone and catalytic cysteine suggests that binding of BUC25 does 
not prevent the productive binding of NAD
+
 to ALDH1A1, as the additional benzyl 
group of BUC25 prevents the compound from binding closer to the catalytic cysteine. 
BUC25 does not inhibit ALDH2 and the mode of binding provides insight into this 
selectivity. The methane sulfonyl group of BUC25 binds in the pocket formed by Gly458 
in ALDH1A1. The corresponding aspartate/asparagine residues in the other ALDH1/2 
isoenzymes would force the coumarin scaffold to adopt a position akin to 2P4 in ALDH2. 
However, unlike the more flexible linker in BUC11, the large benzyl ring cannot adopt a 
conformation to productively bind within the NAD
+
-binding cleft and the benzyl ring of 
BUC25 would encounter more steric hindrance from the conserved tryptophan (Trp177 
in ALDH2) since the residues surrounding Trp177 are bulkier in ALDH2. The tryptophan 
may be able to slightly move in ALDH1B1, ALDH1A2, and ALDH1A3, though not as 
much as in ALDH1A1. This is evidenced by the compound being ~5x less potent for 
these three isoenzymes compared to ALDH1A1. 
 
Surprisingly, unlike 2P3, BUC11, or BUC25, BUC22 was found to bind in the in 
coenzyme binding site of ALDH1A1. The difference in binding location, and the crystal 
forming in a unique space group (P1), raised the possibility that the binding site might be 
influenced by the crystal environment. However, there is a structural basis for the 
selectivity between ALDH2 and ALDH1A1 in this binding location which suggests that 
the binding within the coenzyme site may be more than an artifact of this particular 
crystal form (Figure 36). Ile249 in ALDH2 is replaced by Val250 in ALDH1A1 and 
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although it is the addition of a single methyl group, the substitution narrows this side of 
the site enough to impede binding of the diethylamino substituent in ALDH2. 
Additionally, Val252 and Ala233 in ALDH2 versus Leu253 and Ser234 in ALDH1A1 
may loosen the contacts between the enzyme and BUC22 enough that the binding 
energetics cannot overcome the steric clash with Ile249 through slightly shifting to the 
other side of the blinding cleft.  
 
 
 
Figure 36 Comparison of BUC22 binding to ALDH1A1 versus ALDH2. 
BUC22 (black) binds to ALDH1A1 (purple) in the NAD
+
-binding site. Three amino 
acids in the vicinity of the binding location are not conserved between ALDH1A1 and 
ALDH2 (green) and may explain the selectivity seen between the two enzymes. 
 
 
The kinetic data of BUC22, however, is not completely consistent with this binding 
location. Compounds which bind in the adenine binding site should exhibit competitive 
inhibition towards varied NAD
+
, but BUC22 exhibits noncompetitive inhibition. Though 
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inconsistent with binding in the adenine binding site, it is also a different mode of 
inhibition from compounds determined to bind in the substrate binding site, 2P4 
(competitive) and BUC11 (uncompetitive), which suggests BUC22 binds differently than 
these other analogs. BUC20, a related analog, also exhibits a noncompetitive mode of 
inhibition towards varied NAD
+
 for ALDH1A1 and ALDH2. Due to its linear cyano 
group, BUC20 is not predicted to clash with Ile249 in ALDH2. Consequently BUC20 
inhibits both ALDH1A1 and ALDH2. The reason behind the discrepancy between the 
kinetic data and structural data is unclear, though there is a possibility that BUC22 could 
bind to multiple sites and enzyme species. When NAD
+
 is absent, the compound prefers 
to bind in the NAD
+
 binding site (as in the case of the solved structure), but when NAD
+
 
is present, the compound may bind in another location giving rise to the observed kinetic 
pattern. This additional site could be the substrate binding site, such as where BUC25 
binds. 
 
BUC27 was the only compound that selectively inhibited ALDH2 in this study, other 
than the ester 2BS4. Both BUC27 and 2P4 exhibit competitive inhibition towards varied 
NAD
+
, suggesting that BUC27 likely alters the conformation of the catalytic cysteine to 
interfere with the productive binding of NAD
+
 for catalysis, similar to 2P3. If BUC27 
were to adopt a similar conformation to that of 2P3 bound to ALDH2, the ketoxime 
would occupy the same pocket as the propyl chain. The bromine would be oriented 
towards Met124 would could lead to favorable interaction between the halogen 
substituent and the sulfur side chain atom (Figure 37).  
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Figure 37 Docking of BUC27 in substrate binding site of ALDH2. 
BUC27 was docked in the substrate binding site of ALDH2 so that the aromatic lactone 
was in the same position as that of 2P3 bound to ALDH2. In this position the bromine 
could form a favorable interaction with Met124, which is unique to ALDH2. Future 
compounds could focus on promoting interaction between compound and Met124 to 
achieve selectivity for ALDH2. 
 
 
This potential interaction is not possible for the three ALDH1A isoenzymes as a glycine 
occupies the equivalent position. However, it is unclear what effect the equivalent 
glutamate in ALDH1B1 would have on BUC27 binding. The glutamate of ALDH1B1 
could provide additional contacts for BUC27 binding, thus the rationale for selectivity 
towards ALDH2 by BUC27 is still unclear. The mechanism behind BUC27’s activation 
of ALDH1A3, and that behind BUC3’s activation, is also not clear but may be similar to 
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that of Alda-1, where binding of Alda-1 in the outer portion of the substrate binding site 
increases the amount of productive encounters with the catalytic cysteine for smaller 
aldehydes.  
 
The inhibition pattern of these compounds was compared to that of daidzin, and we found 
that these compounds are more potent than daidzin under our assay parameters. 
Additionally, daidzin was discovered be less selective than previously reported. Daidzin 
inhibited the activity of ALDH2, ALDH1A2, and ALDH1B1 with equal potency, while 
being 100-fold less potent against ALDH1A1 and ALDH1A3. This same pattern of 
inhibition was also found in the psoralen derivatives, where many compounds inhibit 
ALDH2, ALDH1B1 and ALDH1A2 with similar potency and are often less active 
against ALDH1A1 and ALDH1A3 at some level. Although IC50 values may be similar, 
many of the psoralen derivatives only partially inhibited ALDH1A1 and ALDH1A3, or 
did not inhibit at all.  
 
In order to correlate the different binding modes and inhibition patterns to underlying 
structural differences, we examined the binding sites and interactions in more detail. 
Structural comparison of three compound-enzyme complexes revealed the presence of 
two distinct aromatic binding “boxes” or “zones” (Figure 38). In ALDH2 the aromatic 
binding region is located between four phenylalanine residues (170,296,459,465) near the 
catalytic cysteine which surround 2P3 when bound. The activator Alda-1 and the 
isoflavone of the ALDH2 inhibitor daidzin bind in this same aromatic site. 
55, 204
 The 
aromatic binding region of ALDH1A1 is wider, extends farther from the catalytic 
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cysteine and is more surface exposed. In ALDH1A1, Phe459 is replaced by a valine and 
Phe296 is replaced by tyrosine. The aromatic binding region of ALDH1A1 has additional 
aromatic residues at His293 and Phe290. Although the histidine residue is a 
phenylalanine in ALDH2, the side chain of Asp457 in ALDH2 blocks any connection of 
the two regions and gives rise to the smaller site in ALDH2 compared to ALDH1A1, 
which has a glycine in an equivalent position.  
 
 
 
Figure 38 Alignment of three enzyme-inhibitor complexes. 
Alignment of 2P3 (orange) bound to ALDH2 and BUC11 (purple) and BUC25 (cyan) 
bound to ALDH1A1 shows an overlap of separate aromatic binding “boxes” or “zones”. 
D457 in ALDH2 limits the size of the zone in ALDH2, whereas G458 in ALDH1A1 
provide a larger zone for the binding of aromatic compounds. 
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The aromatic lactones are able to shift positions to maximize contacts due to the 
hydrophobicity of the substrate binding site of ALDHs. Most enzymes rely on hydrogen 
bonding and/or ion interactions to align substrates in the substrate binding site; in 
contrast, the substrate binding site of ALDHs is highly hydrophobic with limited 
potential for hydrogen bonding. When substituents are added or removed from an 
activator/inhibitor that result in the compound no longer filling the available space, the 
compound can either not bind at all, or find another site where binding is also possible. 
The hydrophobicity of the tunnel, and lack of dependence on hydrogen bonding and ion 
interactions, provides more potential sites for compound binding in ALDHs. 
 
The ability for the compounds to shift in the hydrophobic substrate binding site may help 
explain the difference in inhibition of ALDH1A1 between 2P3 and 2P4. The shortening 
of the alkyl chain at position R5 from a propyl to a methyl group results in 2P4 not 
inhibiting ALDH1A1. Loss of contact between the scaffold and Val460 in ALDH1A1 (as 
compared to Phe459 in ALDH2) may require the longer propyl chain to “anchor” the 
compound near the catalytic cysteine. The methyl group may not create enough 
additional contacts which will cause the scaffold of 2P4 to shift to the location of BUC11 
when bound to ALDH1A1 to increase the amount of contacts, which is possible due to 
the presence of Gly458. If bound in this location, 2P4 would not inhibit the enzyme as the 
compound would not impede access to the catalytic tunnel.  2P3, even with the longer 
propyl chain, would also not inhibit ALDH1A1 if bound similar to BUC11, which 
supports the idea that the longer alkyl chain enables 2P3 to bind closer to the catalytic 
cysteine to inhibit the enzyme. The additional contacts from the propyl chain may not be 
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needed with ALDH1A2, ALDH1A3, and ALDH1B1 (all of which replace Phe459 in 
ALDH2 with smaller aliphatic residues) as these three enzymes have an asparagine at the 
equivalent position of Gly458 and are each inhibited by 2P4. The additional side chain 
may provide enough binding surface that the smaller compound remains bound to the 
enzyme. 
 
 
A second binding pocket exists in ALDH isoenzymes that can accommodate aromatic 
ring structures—the adenine binding cleft within the coenzyme binding site. When NAD+ 
is bound, the adenine ring is positioned between a conserved proline and a beta-branched 
amino acid (Pro226 and Ile249 in ALDH1A1). The crystal structure of BUC22 shows 
that at least one of the compounds can bind to the adenine site, though kinetic data 
supports the binding of BUC22 at an additional site, most likely the aromatic binding 
region in the substrate binding site.  
 
The multiple aromatic binding sites within ALDH isoenzymes can help explain how the 
ALDH1A1-selective inhibitor BUC22 was discovered from a series of compounds 
identified through a screen targeting ALDH2. BUC22 was not one of the compounds 
found in the high-throughput screen, but a structural analog. Changing the substituents of 
the aromatic scaffold likely caused BUC22 to shift binding locations to the adenine 
binding site, which then provided selectivity against ALDH2. The alteration of 
substituents has been seen to change the selectivity of indole-2,3-diones for a particular 
ALDH isoenzyme.
229
 In that particular case, the compounds had different orientations 
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within the same binding site, while the coumarin and psoralen derivatives show a greater 
amount of movement with multiple binding sites. 
 
An important factor for the use of any compound as a chemical probe is the ability to 
affect the activity of the target enzyme in a cellular context. Coumarins and psoralens can 
either be cell permeable or cell impermeable depending on the exact structure. Some 
psoralens are known to become trapped in cell membranes, with the most hydrophobic 
compounds predicted to be the most permeable.
230
 BUC22 was found to have a 
physiological effect on MDA-MB-468 breast cancer cells after five days of treatment. A 
significant two-fold decrease in the proliferative ability of the breast cancer cells was 
seen when treated with 100 µM BUC22, 100-fold higher than the in vitro Ki (~1 µM), as 
measured by the MTT assay. The loss of potency could arise from a portion of BUC22 
becoming trapped in the cell membrane, by the conversion of the compound into other, 
less potent derivatives upon entrance into the cell, or by export from the cell before 
inhibition occurs. As BUC22 is more hydrophobic than other permeable psoralens, a 
large portion of BUC22 should be able to enter the cell by predicted models. 
Additionally, this concentration is high enough that inhibition of ALDH1A2 by BUC22 
may also contribute to the cell phenotype. Regardless, BUC22 is capable of causing a 
physiologic effect in cancer cells in 3D culture.  
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V. Conclusion and Future Directions 
Members of the ALDH1/2 family are involved in retinoic acid signaling, the metabolism 
of dietary aldehydes, and the removal of toxic aldehydes from oxidative stress. ALDH1/2 
enzymes have also been linked to the development of cancer, obesity, and neurological 
disease. Small molecule probes are needed to study the role of individual enzymes in 
both normal and disease states. The development of selective modulators has been 
difficult due to the structural similarity and overlapping substrate preferences within the 
ALDH1/2 family. At present, there are no commercially available compounds that 
selectively modulate ALDH2 activity compared to other ALDH isoenzymes. 
 
Inhibitors targeting ALDH2, such as daidzin and its derivatives, have been used 
previously to study the function of ALDH2; however, daidzin is not as selective as 
previously reported. We found that daidzin inhibits ALDH2, ALDH1B1, and ALDH1A2 
with equivalent potency. In light of these findings, the selectivity of daidzin derivatives 
including CVT-10216 should be examined further. Many of the aromatic lactones found 
during the course of this study have similar or better selectivity and/or potency than 
daidzin in vitro, suggesting the aromatic lactones, with further development, may be a 
better option for an ALDH2-selective inhibitor. 
 
The aromatic lactones show the ability to bind throughout the aromatic “zones” in the 
catalytic site of ALDH1/2 enzymes. The aromatic “zone” in ALDH2 is smaller due to the 
presence of Asp457, limiting the potential orientations of the lactone within the catalytic 
site. The lactone can only be positioned with its carbonyl oriented directly toward the 
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catalytic cysteine (or rotated 180°). This allows for an easier interpretation of SAR data 
in regards to activity against ALDH2; for example, bulky substituents cause a loss of 
inhibition toward ALDH2 as the compound no longer fits in the narrow binding tunnel 
and any addition to R6 next to the lactone carbonyl must likely fit into the coenzyme 
binding site to maintain binding and subsequent inhibition.   
 
The interpretation for SAR data in regards to ALDH1A1 with these compounds is more 
challenging as multiple binding orientations are possible in the larger substrate binding 
site. The lactones can shift within the hydrophobic pocket to increase the amount of 
contacts while decreasing the amount of clashing based upon the substituents added to 
the scaffold. If a large substituent is placed at position R6, the larger hydrophobic space 
provides an opportunity for the scaffold to shift away from the catalytic cysteine to 
provide room, as in the case for BUC11. Compounds are also likely to shift due to 
decreased contacts with the non-aromatic Val460. Smaller compounds, like 2P3, could 
bind in multiple locations within the catalytic site depending on the specific substituents 
on the aromatic scaffold. Although a crystal structure of 2P3 bound to ALDH1A1 would 
definitely answer where 2P3 binds, it may not help in determining the binding position 
and rationale behind the SAR of other smaller analogs with regards to ALDH1A1, as 
different substituents could shift the scaffold to a different location. If the compound is 
small enough the binding location could shift to the adenosine binding site, as in the case 
for BUC22 bound to ALDH1A1.  
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The structure of 2P3 bound to ALDH2 can reliably be used to predict how structural 
modifications will affect the activity of the lactones for ALDH2; however, care must be 
taken when making future modifications in regards to activity versus ALDH1A1 and the 
rest of the ALDH1/2 family. The addition of a substituent to the scaffold to increase 
interaction with ALDH2, such as an interaction between a halogen and Met124, which is 
not a conserved residue, could have unintended effects on the activity versus other 
isoenzymes through shifting of the aromatic scaffold. 
 
Although the complete rationale for selectivity remains unknown, two selective 
compounds were discovered and characterized—the ALDH1A1-selective BUC22 and the 
ALDH2-selective BUC27. Initial experiments with cells in 3D culture suggest that 
BUC22 can enter cancer cells and impact cell proliferation through inhibition of 
ALDH1A1, though off-target effects are still possible. Previous studies with CM037, an 
ALDH1A1 inhibitor, have found that both ovarian cancer and MDA-MB-468 breast 
cancer cells are more sensitive to ALDH1A1 inhibition in 3D culture as opposed to 
monolayers. This is due in part to an increase in ALDH1A1 expression in cells grown in 
3D culture.
111, 113
 Based on this data, BUC22 should also have differing effects on MDA-
MB-468 cells in 3D vs 2D culture and should be confirmed. BUC22 or future derivatives 
could be used to examine the mechanism by which ALDH1A1 inhibition leads to 
decreased mitochondrial function and proliferative potential. Pharmacodynamic and 
pharmacokinetic experiments could also be completed in mice to determine BUC22’s 
future prospective for in vivo studies. Unlike CM037 and other ALDH1A1-selective 
inhibitors, BUC22 does not rely on Gly458, which is not conserved in rodents, for 
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inhibition or selectivity. BUC22 should be able to inhibit murine ALDH1A1 by binding 
in the more conserved NAD
+
-binding site. There are potential limitations that should be 
addressed before BUC22, or future derivatives, are used in animal models. Mainly, the 
residues Ile249 and Val242 that helped provide selectivity against human ALDH2 are 
substituted by a valine and isoleucine in murine ALDH2, identical to the residues in 
human ALDH1A1. Selectivity against ALDH2 in murine systems is potentially lost, 
though interactions at the second proposed binding site leave this uncertain. Likewise, 
BUC22 may inhibit other NAD
+
-dependent enzymes which would limit its use. The 
variability of the ALDH1/2 family between rodents and humans complicates the animal 
studies that must precede any attempts at human trials, since there are no direct models 
leading from rodents to humans that maintain the human ALDH1/2 structure-activity 
relationship. Possible solutions to this conundrum include the creation of a humanized 
mouse/rat line where the human target of interest is integrated in place of the rodent 
enzyme. 
 
Concerning the ALDH2-selective BUC27, a crystal structure of BUC27 bound to 
ALDH2 would potentially provide a rationale for the selectivity against the other 
ALDH1/2 members. The structure may confirm the proposed interaction between the 
bromine and Met124 and drive development of more potent inhibitors. It would also be 
beneficial to examine if BUC27 is capable of inhibiting ALDH2 within cells by 
measuring potential effects on alcohol metabolism. Unfortunately, to this point there is no 
known liver cell line or primary cell which maintains expression of ALDH2 in culture, 
limiting future studies. For this reason prior development of ALDH2-selective 
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compounds have gone from in vitro studies straight to animal models. BUC27, or 
subsequent derivatives, could be examined for their ability to affect alcohol drinking of 
selectively bred rats to determine bioavailability and potency in vivo. Both BUC27, and 
the ALDH1A1-selective BUC22, should be further developed for use as chemical probes 
to study the individual functions of ALDH2 and/or ALDH1A1. 
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